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ABSTRACT OF DISSERTATION

DEVELOPMENT OF A MULTILAYERED ASSOCIATION POLYMER SYSTEM
FOR SEQUENTIAL DRUG DELIVERY
As all the physiological processes in our body are controlled by multiple
biomolecules, comprehensive treatment of certain disease conditions may be more
effectively achieved by administration of more than one type of drug. Thus, the primary
objective of this research was to develop a multilayered, polymer-based system for
sequential delivery of multiple drugs. This particular device was designed aimed at the
treatment of periodontitis, a highly prevalent oral inflammatory disease that affects 90% of
the world population. This condition is caused by bacterial biofilm on the teeth, resulting
in a chronic inflammatory response that leads to loss of alveolar bone and, ultimately, the
tooth. Current treatment methods for periodontitis address specific parts of the disease,
with no individual treatment serving as a complete therapy.
The polymers used for the fabrication of this multilayered device consists of
cellulose acetate phthalate (CAP) complexed with Pluronic F-127 (P). After evaluating
morphology of the resulting CAPP system, in vitro release of small molecule drugs and a
model protein was studied from both single and multilayered devices. Drug release from
single-layered CAPP films followed zero-order kinetics related to surface erosion property
of the association polymer. Release studies from multilayered CAPP devices showed the
possibility of achieving intermittent release of one type of drug as well as sequential release
of more than one type of drug. Mathematical modeling accurately predicted the release
profiles for both single layer and multilayered devices. After the initial characterization of
the CAPP system, the device was specifically modified to achieve sequential release of
drugs aimed at the treatment of periodontitis. The four types of drugs used were
metronidazole, ketoprofen, doxycycline, and simvastatin to eliminate infection, inhibit
inflammation, prevent tissue destruction, and aid bone regeneration, respectively. To
obtain different erosion times and achieve appropriate release profiles specific to the
disease condition, the device was modified by increasing the number of layers or by
inclusion of a slower eroding polymer layer. In all the cases, the device was able to release
the four different drugs in the designed temporal sequence. Analysis of antibiotic and antiinflammatory bioactivity showed that drugs released from the devices retained 100%
bioactivity.

Following extensive studies on the in vitro sequential drug release from these
devices, the in vivo drug release profiles were investigated. The CAPP devices with
different release rates and dosage formulations were implanted in a rat calvarial onlay
model, and the in vivo drug release and erosion was compared with in vitro results. In vivo
studies showed sequential release of drugs comparable to those measured in vitro, with
some difference in drug release rates observed. The present CAPP association polymerbased multilayer devices can be used for localized, sequential delivery of multiple drugs
for the possible treatment of complex disease conditions, and perhaps for tissue engineering
applications, that require delivery of more than one type of biomolecule.

KEYWORDS: Multiple drug delivery, Periodontitis, Cellulose acetate phthalate,
Pluronic F-127, Sequential drug release, in vitro drug release, in vivo
drug release.
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Chapter 1 Introduction
The human physiology is an intricate system involving a network of many organs
and organ systems. Human body works and maintains its homeostatic condition depending
on complex cascade of events with several signaling molecules, involving more than one
organ or a system. In the event of an injury or disease the physiological response required
to bring the body back to normal condition also involves several factors working in an
interrelated manner. One such condition which requires more than one factor that needs to
be addressed for treatment is periodontitis. Treatment of this condition involves eradicating
the microbial infection, controlling the inflammatory response, preventing bone resorption
and aiding bone regeneration. The main aim of this research was to develop surface erosion
based implantable polymeric device capable of delivering more than one type of drug in
the required temporal sequence for treatment of such complex medical condition. Chapter
2 examines the background and significance of the releasing multiple drugs in the
sequential order and also explores its usefulness in treatment of periodontitis. The details
of the previous research and the use of surface eroding polymer used in this research are
discussed. The types of drugs that are delivered using this device and their relevance in
regard with the treatment of periodontitis are also briefly explained.
General mass loss and drug release properties of the association polymer system
(CAPP) comprising of cellulose acetate phthalate (CAP) and Pluronic F-127 is analysed in
chapter 3. Different small molecule drugs and a model protein were loaded in the CAPP
films at different doses and their zero order release was studied. The fabrication of CAPP
films in the form of multilayered devices for intermittent and sequential release of drugs
are also discussed in chapter 3. These drug release profiles are predicted using a
mathematical model and compared with the actual release profiles. Chapter 4 involves the
fabrication of the CAPP multilayered device capable of releasing four drugs released in a
sequential order, specifically aimed at the treatment of periodontitis. This included release
of antibiotics, anti-inflammatory, anti-resorptive and osteogenic drug in the required
temporal sequence. The bioactivity analysis of the released drug were performed and the
multilayered device was also modified to obtain different erosion and release times by
inclusion of slower eroding polymer layer.
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Chapter 5 presents the in vitro and in vivo sequential release of four different drugs
from the multilayer CAPP device. The in vivo drug release studies were performed by
implantation of the multilayer device in the rat calvarium model. Multilayer CAPP device
capable of releasing four different drugs in a sequential manner in vivo in different doses
and erosion times were studied and compared with in vitro release. Based on the
comparison of in vitro and in vivo release profiles, the possible changes that might be
necessary in the device to achieve the appropriate in vivo release profile for treatment of
specific disease conditions are also discussed.
The ability of this CAPP based multilayer device for delivering more than one type
of drug sequentially is further discussed in the conclusion, along with its possibility to serve
as a complete treatment for periodontitis. This device will not only be useful in the
treatment of periodontal disease, it will also serve as a model for fabrication of devices
with the general capability for delivering multiple drugs for treatment of complex disease
conditions and for tissue engineering.

Copyright © Sharath kumar Chinnakavanam Sundararaj 2013
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Chapter 2 Background and Significance

2.1 Treatments requiring multiple drug delivery
Pathogenesis of a disease condition is based on cascade of events with more than
one type of biomolecules taking part in them. This creates the need for administration of
multiple drugs for better and complete treatment of a particular disease condition. Some of
the examples include severe bacterial infection required combination of antibiotics
(Dowling 1957), infection accompanied by tissue loss (Younger, Duncan et al. 1998),
cancer therapy (Wang, Rosano et al. 2010) and periodontitis (Rosen 2001). In the case of
bacterial infection and biofilm formation more than one type of antibiotic agent may be
required for complete elimination of infection (Griffiths, Ayob et al. 2011). Administration
of more than one type of antibiotic would help fight different types of bacteria present and
might also avoid the chances of bacteria developing resistance towards a particular drug
(Dowling 1957, Griffiths, Ayob et al. 2011). Similarly in the case of bacterial infection
which is accompanied with tissue loss, we need antibiotics to treat the infection followed
by growth factors to aid tissue regeneration (Younger, Duncan et al. 1998). Another similar
type of condition is periodontitis, an inflammatory condition caused due to bacterial
infection that ultimately leads to tissue loss (Rosen 2001, Polimeni, Xiropaidis et al. 2006),
would require antibiotics, anti-inflammatory and osteogenic agents for complete treatment.
There is a growing body of research which suggests the need for multiple drug delivery or
combinatorial drug therapy for effective cancer treatment (Chen and Jin 2010, Wang,
Rosano et al. 2010, Cao and Bae 2012, Lee and Nan 2012). The process of wound healing
also shows the presence multiple stages such as hemostasis, inflammation, proliferation
and wound remodeling involving multiple biomolecules (Gurtner, Werner et al. 2008,
Velnar, Bailey et al. 2009).
Along with the treatment of the above mentioned conditions, more and more
research indicate the need for multiple growth factors for tissue engineering applications.
The importance of multiple growth factors for effective tissue regeneration has been
reviewed by Chen et al. (Chen and Jin 2010). There are more of these studies on tissues
like bone, cartilage and blood vessels. Studies have shown the effect of mixture of growth
factors on increase in number of human alveolar bone cells in vitro (de Oliveira, de Oliva
3

et al. 2008). Yeh et al., showed the synergistic effect of osteogenic protein 1 and
interleukin-6 (IL-6) in stimulating differentiation of rat osteoblastic cells (Yeh, Zavala et
al. 2002), and the combined effect of insulin like growth factor I (IGF-I) and transforming
growth factor (TGF-β) on chrondrogenesis in vitro was shown by Fukomuto et al.
(Fukumoto, Sperling et al. 2003). The well-studied process of angiogenesis also shows the
presence of multiple growth factors working together in a complex cascade of events
starting with vasculogenesis (vessel formation), followed by angiogenic remodeling and
maturation of blood vessels (Yancopoulos, Davis et al. 2000). Even for regeneration of
nervous tissue and guidance of axons there are multiple factors involved (Dontchev and
Letourneau 2003). For regeneration of more complex tissues like muscles both
angiogenesis and myogenesis growth factors would be required (Borselli, Storrie et al.
2010).
The above examples show the need of multiple drugs for complete treatment of a
condition or multiple growth factors for regeneration of a tissue. Growth factors are
expressed in a time-dependent manner during the process of tissue regeneration. The
sequential expression of growth factors in differentiation of osteoprogenitors to osteoblasts
in vitro was investigated by Huang et al. (Huang, Nelson et al. 2007). The process of bone
fracture healing (Cho, Gerstenfeld et al. 2002) and tendon to bone healing (Würgler-Hauri,
Dourte et al. 2007) also involves temporal expression of several growth factors. Sequential
delivery of growth factors has also shown to have positive effect on cartilage tissue
engineering (Martin, Suetterlin et al. 2001, Worster, Brower‐Toland et al. 2001, Pei, Seidel
et al. 2002). Sequential expression of growth factor can also be observed in the case of
wound healing as seen in the spatiotemporal expression of periostin during skin
development (Zhou, Wang et al. 2010). Similar to the requirement of multiple growth
factors for tissue regeneration, treatment of a complex disease condition also required
temporal administration of different drug to counter the cascade of event that that form the
basis for the pathogenesis of the condition. Thus sequential delivery of multiple
drugs/growth factors in different temporal profiles would be critical for treatment of
complex disease conditions and regeneration of tissues.

4

2.2 Current research on simultaneous and sequential multiple drug delivery systems
Localized delivery of drug using biodegradable polymer systems has been studied
widely and various drug delivery systems have been successfully fabricated for treatment
of several disease conditions and regeneration of different types of tissues (Langer and
Chasin 1990, Schacht 1990, Jain, Yenet Ayen et al. 2011). There are examples of drug
delivery systems capable of releasing small molecule drugs and growth factors. For
example widely used small molecule drugs like antibiotics has been delivered using
different types of biodegradable polymers (Giamarellos-Bourboulis 2000, Tsourvakas
2000, El-Husseiny, Patel et al. 2011). Similarly in the case of tissue engineering there are
different types of delivery systems for local release of growth factors for bone regeneration
(Geiger, Li et al. 2003, Saito, Murakami et al. 2005, Ginebra, Traykova et al. 2006). In
spite of considerable success at both treatment of a disease and tissue regeneration, more
and more research suggests the need for more than one type of drug for a comprehensive
treatment of a complex disease condition like the ones that are discussed in the section 2.1
or complete regeneration of a tissue. The multiple drug delivery devices aimed at treatment
of complex disease condition and regeneration of tissue are mostly designed for
simultaneous delivery of multiple agents (Lynch, de Castilla et al. 1991, Raschke,
Wildemann et al. 2002, Nevins, Camelo et al. 2003, Simmons, Alsberg et al. 2004, Dogan,
Gumusderelioglu et al. 2005, Peattie, Rieke et al. 2006, Riley, Fuegy et al. 2006, Nillesen,
Geutjes et al. 2007, Patel, Young et al. 2008, Chen, Chen et al. 2009, Young, Patel et al.
2009, Borselli, Storrie et al. 2010, Chen, Zhang et al. 2010) rather than sequential delivery.
Poly(lactic-co-glycolic acid) (PLGA) is one of the most commonly used and well
characterized biodegradable polymers used for fabrication of various drug delivery systems
(Middleton and Tipton 2000, Makadia and Siegel 2011), and many of these multi-drug
delivery systems discussed above are in part or completely fabricated using PLGA. PLGA
in the form of porous scaffolds has been used for delivery of vascular endothelial growth
factor (VEGF) and platelet-derived growth factor (PDGF) for angiogenesis (Richardson,
Peters et al. 2001). PLGA has also been used along with β-tricalcium phosphate in the form
of composite scaffolds for controlled dual release of dexamethasone and bovine serum
albumin (as a model protein) (Yang, Tang et al. 2011). Different growth factors (IGF-I and
TGF-β) have been loaded in PLGA microspheres and embedded in a poly(ethylene oxide)
5

hydrogel matrix to attain dual drug delivery (Elisseeff, McIntosh et al. 2001). A similar
strategy was used by loading gelatin microspheres with VEGF and bone morphogenetic
protein 2 (BMP-2) and confining them in a porous poly(propylene fumarate-co-ethylene
glycol) hydrogel scaffold for bone regeneration in a critical size defect model (Patel, Young
et al. 2008).
Hydrogels have also been used for developing dual drug delivery systems. Alginate
hydrogels have been used separately for delivery of BMP-2 and TGF-β3 for in vivo bone
formation (Simmons, Alsberg et al. 2004) and in combination with calcium sulphate to
deliver both IGF-I and VEGF for muscle regeneration (Borselli, Storrie et al. 2010).
Glycidyl methacrylated dextran (Dex-GMA)/gelatin hybrid hydrogel scaffolds with the
capability of delivering IGF-I and BMP-2 have been fabricated aimed at periodontal tissue
engineering (Chen, Chen et al. 2009). Other than the above mentioned PLGA and hydrogel
based systems a cell adhesive scaffold based on poly (2-hydroxyethyl-methacrylate)and
poly(L-lysine) has been used for delivery of nerve growth factor (NGF) and neurotrophin3 (NF-3) to direct axonal growth (Moore, MacSween et al. 2006). There is also a dual
delivery system in the form of polylactide coating for delivery of IGF-I and TGF-β to
accelerate osteotomy healing (Raschke, Wildemann et al. 2002). Along with the above
mentioned microscale dual delivery systems, there are different liposomal based nanoscale
delivery system for delivery of multiple drugs for cancer treatment (Chen and Jin 2010,
Lee and Nan 2012).
The multi-drug delivery systems which have been discussed till now are mostly the
ones that involve simultaneous release of the drugs or growth factors. As mentioned in the
section 2.1 all the physiological conditions in our body are a cascade of events. So to treat
a condition effectively the drugs must also be delivered in a sequential manner depending
on the pathogenesis of the condition and the growth factors must be expressed in the
appropriate temporal sequence for successful tissue regeneration. Considering the research
done on drug delivery using biodegradable polymers, only a limited amount research has
been conducted on sequential drug delivery systems (Chen, Silva et al. 2007, Buket
Basmanav, Kose et al. 2008, Jaklenec, Hinckfuss et al. 2008, Kempen, Lu et al. 2009,
Tengood, Kovach et al. 2010). As observed in the case of simultaneous multi-drug delivery
systems, even in the case sequential drug delivery systems PLGA is the predominantly
6

used biodegradable polymer. PLGA has been used in the form microsphere-based scaffolds
for sequential release of bioactive IGF-I and TGF-β1 (Jaklenec, Hinckfuss et al. 2008), in
the form of porous bilayered scaffold to achieve spatiotemporal VEGF and PDGF delivery
for blood vessel formation and maturation (Chen, Silva et al. 2007) and in the form of
microspheres incorporated into a solid poly(propylene fumarate) (PPF) rod surrounded by
a cylindrical gelatin hydrogel for local sequential VEGF and BMP-2 delivery (Kempen,
Lu et al. 2009). The sequential release of BMP-2 and BMP-7 has been studied using two
different delivery systems both involving PLGA. One system uses PLGA nanoparticles
along

with

Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)

(PHBV)

nanoparticles

embedded in the poly(ε-caprolactone) matrix for sequential release for in vitro bone
regeneration (Yilgor, Tuzlakoglu et al. 2009, Yilgor, Hasirci et al. 2010), and the other
system is based on microspheres of polyelectrolyte complexes of poly(4-vinyl pyridine)
(P4VN) and alginic acid loaded with the growth factors BMP-2 and BMP-7 embedded into
the scaffolds constructed of PLGA. (Buket Basmanav, Kose et al. 2008). Other examples
of delivery systems for sequential drug release include the calcium sulphate nanoparticles
incorporated in a double layer collagen membrane (Cao and Bae 2012) or the use of
alginate hydrogels for sequential release of VEGF and PDGF (Hao, Silva et al. 2007).
Sequential release kinetics of two (gentamicin and BMP-2) or three (gentamicin, IGF-I and
BMP-2) bioactive molecules using one component poly (lactic acid) (PLA) coating on kwires were studied to treat infection and aid bone healing (Strobel, Bormann et al. 2011).
PLGA is a copolymer of glycolic acid and lactic acid linked together by ester
linkages. PLGA undergoes bulk degradation resulting in characteristic initial burst release
and diffusion of the loaded drug before complete polymer degradation (Makadia and Siegel
2011). Even though sequential release is achieved to a certain extent, clear distinction
between the temporal release profiles of different drugs/growth factors is not found in the
sequential delivery systems mentioned in this section. For distinct sequential delivery of
drugs a surface eroding system capable of releasing drugs only when the polymer erosion
occurs would be more suitable, as it would avoid simultaneous diffusion of multiple drugs
and aid release of one drug at a time if designed in an appropriate way. Polyanhydrides and
poly(orthoesters) are the most common surface eroding polymers used to delivery drugs at
a constant rate that is proportional to polymer erosion. Polyanhydrides are copolymers of
7

aromatic and aliphatic anhydrides that degrade in to non-toxic diacidic monomers.
Poly(orthoesters) are hydrophobic surface eroding polymer prepared by tranesterification
reaction or by the addition of polyols to diketene acetals (Uhrich, Cannizzaro et al. 1999,
Heller, Barr et al. 2002, Kumar, Langer et al. 2002, Jain, Modi et al. 2005).
For designing a device capable of loading and releasing multiple drugs, the polymer
system chosen must be compatible with all the drugs that are part of the system, and the
processing conditions involved must not affect the bioactivity of any of the drugs. Difficult
processing conditions, like high processing temperature and poor solubility of
polyanhydrides and poly(orthoesters), makes them a unsuitable for designing complex
delivery systems without affecting the bioactivity of the drugs. An association polymer
system (CAPP) formed via hydrogen bonds between cellulose acetate phthalate (CAP) and
Pluronic F-127 (P) when mixed in an aprotic solvent, is a surface eroding system used for
drug delivery (Xu and Lee 1993, Gates, Grad et al. 1994). The CAPP system has been
previously used in the form compressed microsphere scaffolds for intermittent and
sequential drug delivery of (Raiche and Puleo 2003, Raiche and Puleo 2004, Jeon,
Piepgrass et al. 2008).

2.3 Periodontitis and drugs used for its treatment
Periodontitis is inflammatory condition caused by bacterial infection, which results
in loss of soft tissue, alveolar bone and ultimately the tooth (Rosen 2001). Periodontitis is
the most prevalent inflammatory disease in the world and is the leading cause of tooth loss
in adults (Brown, Oliver et al. 1989, Albandar and Kingman 1999). Current methods
involve treatment of infection using antibiotics, but in severe cases surgical intervention is
required (Chen and Jin 2010). Some of the common treatment methods include mechanical
debridement of periodontal pockets along with plaque control to fight the bacterial
infection (Etienne 2003). There is no current treatment method available for complete cure
of periodontitis (Chen and Jin 2010). Periodontitis is also considered as a risk factor for
cardiovascular disease (Beck, Garcia et al. 1996) and preterm low birth weight (Beck,
Garcia et al. 1996). Periodontitis being a condition with complex sequential relationship
between infection, inflammation and tissue loss, it might require administration of multiple
drugs in an appropriate sequence for proper treatment (Jeon, Piepgrass et al. 2008, Cochran
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D L. (2003)). Local delivery of drugs has been attempted for treatment of periodontitis
(Greenstein and Polson 1998). Vyas et al. reviewed the current research on controlled
delivery systems for treatment of periodontitis (Vyas, Sihorkar et al. 2000). All these
delivery systems are aimed at the delivery of one type of drug for treatment of one specific
part of the periodontitis.
Of the four types of drugs that are required for the complete treatment of
periodontitis, the antibiotic is the first drug that has to be administered to fight the bacterial
infection. There are different antibiotics, like amoxicillin (Griffiths, Ayob et al. 2011),
Moxifloxacin

(Ardila,

Fernandez

et

al.

2010),

clindamycin,

metronidazole,

phenoxymethylpenicillin and tetracycline (Slots and Ting 2002, Kulik, Lenkeit et al. 2008)
(Eick and Pfister 2004) that have been used against the bacterial infection as a part of the
periodontal treatment. Among these amoxicillin, tetracycline and metronidazole were the
most effective antibiotics against different types of periodontal bacteria such as A.
actinomycetemcomitans, P. gingivalis and P. intermedia/P. nigrescens (Kulik, Lenkeit et
al. 2008). Amoxicillin, doxycycline and Metronidazole have been effectively tested against
different strains of P gingivalis (Larsen 2002). Local delivery of antibiotics has been
attempted for the treatment of periodontal infection (Bernie , Schwach-Abdellaoui, VivienCastioni et al. 2000, Etienne 2003). Studies have shown that biofilm-associated P
gingivalis might be resistant against metronidazole concentration that is being attained by
systemic administration (Wright, Ellen et al. 1997). Metronidazole has been delivered
locally for periodontal treatment in the form of gel (Sato, Fonseca et al. 2008), electrospun
poly(L-lactide-co-D/L-lactide) fibers (Reise, Wyrwa et al. 2012) and mucoadhesive buccal
formulation (Perioli, Ambrogi et al. 2004).
The other type of drug that is administered for treatment of periodontitis is an antiinflammatory drug to counter the inflammatory response that was caused due to bacterial
infection (Van Dyke 2008). Non-steroidal anti-inflammatory drugs (NSAIDs) have been
one of the common class of drugs used in periodontal treatment (Williams, Jeffcoat et al.
1984, Offenbacher, Williams et al. 1992, Howell and Williams 1993, Salvi and Lang 2005).
Studies have shown that NSAIDs also have a positive effect by altering the human alveolar
bone loss progression (Lynch, Williams et al. 1989, Howell, Jeffcoat et al. 1991, Dionne
and Berthold 2001). Some of the commonly used NSAIDs for treating periodontitis include
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flurbiprofen (Jeffcot, Williams et al. 1986, Lynch, Williams et al. 1989), ketoprofen (Reed,
Smith et al. 1997), indomethacin (Williams, Offenbacher et al. 1988) and naproxen
(Howell, Jeffcoat et al. 1991). Local delivery of these drugs have been attempted to treat
periodontitis using acrylic bone cement as the delivery vehicle (Corry and Moran 1998) or
delivery of these drugs using microspheres (Paquette, Oringer et al. 2003) or cellulose
acetate films (Cetin, Buduneli et al. 2004). Flurbiprofen has been administered locally in
topical form as an adjunct to non-surgical management of periodontal disease (Heasman,
Benn et al. 1993). Similarly topical administration of ketoprofen in the form of cream
(Howell, Martuscelli et al. 1996) or gel (Lawrence, Paquette et al. 1998) have shown
positive results towards potential inhibition of disease progression (Paquette, Fiorellini et
al. 1997, Paquette, Lawrence et al. 2000).
The loss of alveolar bone caused because of the adverse inflammatory response
(Cochran 2008) is treated using anti-resorptive agents. Bisphosponates are a class of antiresorptive drugs, which have been used for the treatment of periodontitis (Tenenbaum,
Shelemay et al. 2002, Lane, Armitage et al. 2005, Shinoda and Takeyama 2006, Jeffcoat,
Cizza et al. 2007, Badran, Kraehenmann et al. 2009). Residronate administered at an
appropriate dosage has shown to inhibit bone resorption in periodontitis (Cetinkaya, Keles
et al. 2008). Studies have also shown that the topical administration of olpadronate has
effectively prevented bone loss caused by periodontitis (Goya, Paez et al. 2006). Local
administration of bisphosphonate such as alendronate using gelatin sponges has also been
shown to reduce bone loss in periodontal procedures such as mucoperiosteal flap surgery
(Reddy, Weatherford et al. 1995, Yaffe, Fine et al. 1995, Yaffe, Iztkovich et al. 1997,
Binderman, Adut et al. 2000, Kaynak, Meffert et al. 2000). Tetracycline has significant
anti-matrix metalloproteinase activity and also inhibits osteoclast development, structure,
and function, thereby helps prevent bone resorption (Vernillo and Rifkin 1998)
Tetracycline has also been shown to be particularly effective against alveolar bone loss
associated with periodontitis (Ramamurthy, Rifkin et al. 2002). Tetracycline when applied
locally along with bisphosphonate reduced alveolar bone loss (Yaffe, Herman et al. 2003).
Doxycycline, a type of tetracycline with antibacterial properties, when administered in
subantimicrobial dose has been shown to improve efficacy of scaling and root planning
along with having a positive effect on the management of severe, generalized, chronic
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periodontitis (Caton, Ciancio et al. 2000, Novak, Johns et al. 2002). Doxycycline when
delivered locally was equally effective as scaling and root planning (Garrett, Johnson et al.
1999), and when combined with a NSAID had enhanced effect in inhibition of matrix
metalloproteinase for treatment in chronic periodontitis patients (Lee, Ciancio et al. 2004).
The final stage of periodontitis treatment would involve the regeneration of the lost
tissue, which would include the regeneration of the alveolar bone. There are different
growth factors that have been locally delivered using biodegradable polymers like PLGA,
PLA and poly(caprolactone) (PCL) for regeneration of bone (Tezcaner and Keskin 2011).
One of the most common growth factor used for bone regeneration is BMP (Haidar, Hamdy
et al. 2009, Brown, Li et al. 2011). Different growth factors including the BMPs, have
been used for alveolar bone regeneration and reconstruction (Graves, Kang et al. 1994,
Sigurdsson, Lee et al. 1995, Giannobile 1996, Howell, Martuscelli et al. 1996, Toriumi,
O'Grady et al. 1999, Raja, Byakod et al. 2009). Specifically BMP-2 has been used for
periodontal reconstruction with significantly enhanced regeneration (Sigurdsson, Lee et al.
1995, Wikesjo, Guglielmoni et al. 1999, Selvig, Sorensen et al. 2002, Saito, Saito et al.
2003). BMP-2 has been delivered using gelatin based carrier system (Talwar, Di Silvio et
al. 2001) or in the form of gene therapy for periodontal regeneration (Jin, Anusaksathien
et al. 2003, Dunn, Jin et al. 2005, Chen, Chen et al. 2008, Lutz, Park et al. 2008). Other
than BMP-2, platelet-derived growth factor has been studies for the purpose of periodontal
regeneration (Giannobile, Lee et al. 2001, Nevins, Camelo et al. 2003). Combination of
growth factors have also been used for periodontal regeneration, such as the application of
human osteogenic protein-1 and BMP-2 (Ripamonti, Crooks et al. 2001) and the use of
PDGF and IGF to enhance bone formation (Lynch, Williams et al. 1989, Lynch, de Castilla
et al. 1991). Apart from the growth factors used for periodontal regeneration, simvastatin
a small molecule drug has been shown to promote osteoblast viability and differentiation
via membrane bound BMP-2 pathway (Chen and Jin 2010). Simvastatin has also been
studied for its potential as osteogenic agent in treatment of periodontitis (Singh, Dodwad
et al. , Yazawa, Zimmermann et al. 2005, Chen and Jin 2010). Simvastatin has been shown
to promote osteoblast viability and differentiation via membrane bound BMP-2 pathway
Studies have shown that the administration of simvastatin had a positive effect on the
periodontitis-associated bone loss in rat model (Vaziri, Naserhojjati-Roodsari et al. 2007).
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Local delivery of simvastatin in the form of injection (Morris, Lee et al. 2008) and gels
(Thylin, McConnell et al. 2002) resulted in improved treatment outcome both in rat model
(Stein, Lee et al. 2005, Seto, Ohba et al. 2008) and human clinical trials (Pradeep and
Thorat 2010).

2.4 Significance
Published research on simultaneous and sequential release of drugs mostly involves
only delivery of two types of drugs or growth factors. This research focuses on sequential
release of four different drugs at different rates and doses to create a versatile system. Most
of the multiple drug delivery systems are formed using more than one type of polymer and
use combinations of microspheres or nanoparticles embedded in scaffold or matrix in a
form of complex architecture resulting in a relatively difficult fabrication process. The
multilayered device used in this research would be primarily formed using CAPP
association polymer in the form of drug loaded films with a relatively simpler fabrication
process. Even though the device is capable of delivering different types of drugs, this
research is aimed at designing a device capable delivering four drugs in a predetermined
sequence for stepwise treatment of periodontitis. Periodontitis was chosen as a
representative example of a condition that may benefit by sequential drug delivery. The
focus of this research is on developing a device specifically for sequential release of
antibiotics, anti-inflammatory, anti-resorptive and osteogenic drugs for periodontal
treatment by elimination of infections and inflammation, prevention of bone resorption and
augmentation of alveolar bone growth.
The drugs that were selected to be loaded in this device have already been
successfully used separately for the treatment of a specific stage of periodontitis as
discussed in section 2.3. The metronidazole (antibiotic) and ketoprofen (antiinflammatory) used as a part of this device are the currently being in use for periodontitis
treatment. The third drug that is a part of this device, doxycycline, is a tetracycline with
both anti-resorptive and antibiotic properties. This will help prevent bone resorption and
also the antibiotic property of this drug will provide of protection, along with
metronidazole against infection during the course of repair and regeneration. The final
osteogenic drug selected is simvastatin. Simvastatin, being a small molecule drug it is
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relatively more robust during fabrication process than the growth factors that have been
used for periodontal regeneration. This device will deliver these drugs in a sequential order
to form an all-encompassing treatment for periodontitis. The device can be altered by
inclusion of poly(sebasic acid) (PSA) layer or by changing the ratio of CAP:Pluronic to
achieve different erosion times and release profiles as required by the severity of the
condition. The amount of drug loaded and released from the CAPP films can also be altered
based on the dose requirement, which would be of critical importance for effective
treatment. The final part of this research included the study in vivo drug release profiles
from these multiple drug delivery devices.
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Chapter 3 Bioerodible System for Sequential Release of Multiple Drugs

3.1 Introduction
Several conditions,

such as severe

bacterial infection,(Dowling

1957)

periodontitis,(2001) and traumatic bone loss along with infection,(Younger, Duncan et al.
1998) require repeated administration of a drug or administration of more than one drug
for efficacious treatment. As reviewed by Chen et al., delivery of multiple growth factors
is also important for tissue engineering.(Chen, Zhang et al. 2010) Thus, this research was
directed at developing a bioerodible system capable of delivering one or more types of drug
in a predetermined temporal sequence, which could be helpful for treatment of different
stages of complex diseases and also in tissue engineering.
Polyanhydrides and polyorthoesters are two common classes of surface-eroding
polymers employed for controlled delivery of drugs for a variety of purposes, including
antimicrobial, anti-inflammatory, analgesic, cancer, and ocular applications.(Uhrich,
Cannizzaro et al. 1999, Heller, Barr et al. 2002, Kumar, Langer et al. 2002, Jain, Modi et
al. 2005) Surface-eroding polymers provide a constant rate of drug release that is directly
proportional to polymer erosion.(Jain, Modi et al. 2005) As such, they provide highly
controllable and reproducible drug release profiles(Uhrich, Cannizzaro et al. 1999) that
would be useful for designing multiple drug delivery systems. Ease of processing is an
important consideration for designing and developing a versatile drug delivery system
capable of delivering more than one type of drug, but the high processing temperature and
poor solubility in organic solvents cause difficulty in fabrication of some polyanhydrides
and polyorthoesters into dosage forms.(Gopferich and Tessmar 2002, Heller, Barr et al.
2002)
An alternative, but less well known, surface-eroding system is composed of
cellulose acetate phthalate (CAP) and Pluronic F-127 (P). When mixed in an aprotic
solvent, the polymers associate via hydrogen bonds.(Xu and Lee 1993) The properties of
the CAPP system, such as ease in fabrication and drug loading, make it a suitable candidate
for designing a surface-eroding multiple drug delivery system. The CAPP association
polymer system has already been studied for the release of a single drug.(Xu and Lee 1993,
Gates, Grad et al. 1994) For example, Xu et al. demonstrated the effect of the CAP to
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Pluronic ratio on erosion rate and drug release.(Xu and Lee 1993) The CAPP association
polymer has also been used in the form of consolidated microspheres for the release of
protein.(Raiche and Puleo 2003) Jeon et al. fabricated CAPP microsphere-based devices
for intermittent release of simvastatin and showed positive results for osteoblast responses
and bone formation in vitro and in vivo, respectively.(Jeon, Thomas et al. 2007, Jeon,
Piepgrass et al. 2008) The same group also studied intermittent release of two different
drugs using CAPP microsphere-based devices.(Jeon, Piepgrass et al. 2008) There is less
research, however, toward delivery of more than two drugs or biomolecules in a
predetermined temporal sequence.
In the present studies, different small molecule drugs, such as metronidazole
(antibiotic), doxycycline (antibiotic/anti-resorptive), ketoprofen (anti-inflammatory) and
simvastatin (hypolipidemic/osteogenic) along with a model protein (lysozyme) were
loaded in CAPP films. After evaluating individual layers, the morphology of multilayered
devices and subsequent intermittent and sequential release profiles were measured. To
determine effects of encapsulation and release on bioactivity, enzymatic activity of the
released model protein was determined.
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3.2. Materials & Methods
3.2.1 Fabrication of CAPP films
CAPP films were fabricated by solvent casting. CAP (Sigma, St. Louis, MO) and
Pluronic F-127 (Sigma) were mixed in the weight ratio of 70:30, respectively, and
dissolved in acetone to obtain an 8% polymer solution. Either 2.5 or 5 wt% of drug was
added to the acetone-polymer (CAPP) solution and mixed thoroughly until the drug was
completely dissolved, except for the case of the model protein, which did not completely
dissolve. The drug-polymer solution was poured in a Teflon dish and stored at 4ºC for 24
hours for solvent evaporation to take place. Blank CAPP films were prepared in the same
way but without the addition of drugs. For the present study, CAPP films were loaded with
metronidazole (Sigma), doxycycline (Sigma), ketoprofen (Sigma), lysozyme (Sigma), or
simvastatin (Haorui Pharma-Chem, Inc., Edison, NJ). Samples with 6 mm diameter and
0.5 mm thickness were punched from the CAPP films for further study.
Multilayered CAPP films were fabricated to obtain intermittent release of the same
drug or sequential release of more than one drug. Figure 3.1 shows a schematic
representation of the fabrication process. The drug-loaded and blank CAPP films were
arranged in the desired sequence and then bonded together by compressing them after 5 μL
of acetone were applied between the layers. For intermittent release of drugs, four-layered
CAPP devices were prepared with alternating layers of blank and metronidazole-loaded
films. For achieving sequential release of more than one type of drug, three-layered CAPP
devices were fabricated using metronidazole- and ketoprofen-loaded CAPP films with
blank films between the drug-containing layers. The stacked CAPP films were inserted into
a 6 mm diameter polystyrene well, which acted as in impermeable backing to enable
unidirectional polymer erosion and drug release. A similar procedure was followed to
fabricate multilayered devices loaded with simvastatin and doxycycline.
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Figure 3.1: Schematic representation of the process for fabricating multilayered CAPP
devices.
3.2.2 Morphological characterization of CAPP films
Scanning electron microscopy (SEM)
SEM imaging was used to study the overall morphology and interfaces of the blank
and drug-loaded CAPP films that form the device. For this purpose, four-layered devices
were fabricated with alternating metronidazole-loaded and blank films. The CAPP films
were freeze-fractured, and the cross-section was sputter-coated with platinum and observed
using an S-3200-N Hitachi instrument.
Fluorescence imaging
To analyze the spatial distribution of drug following device fabrication, a
fluorescent molecule was incorporated into multilayered films. Fluorescein (Sigma) was
loaded in CAPP films at 0.16 wt%, and multilayered CAPP films were fabricated with
alternating layers of fluorescein-loaded and blank films. Thin (5 µm) cross-sections of the
multilayered CAPP films were cut with a microtome and observed under epifluorescence
(Olympus IX51). To determine the effect of aging on interlayer diffusion of fluorescein,
samples were incubated at 37°C for 6 days followed by sectioning and microscopic
analysis. Line profiling of the fluorescent microscopic images was conducted using ImageJ
software.
3.2.3 Drug release from single and multilayered CAPP films
In vitro release studies were conducted for single-layered CAPP films by eroding
the materials in 4 mL of phosphate-buffered saline (PBS), pH 7.4, at 37ºC on an orbital
shaker. Release supernatant was collected every one hour and replaced with fresh PBS.
Blank CAPP films of the same dimensions were used as controls. Multilayered devices
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were eroded in either 2 or 4 mL of PBS to study the effect of sink volume on device erosion
and drug release. For multilayered devices, release supernatants were collected
approximately every 8-10 hours and replaced with fresh PBS. Mass loss studies were
conducted by measuring the remaining mass of the multilayered CAPP at regular intervals
during its course of erosion in 2 ml of PBS. Three-layered blank devices were used as
controls for the release and erosion studies. Because lysozyme loaded in the films did not
dissolve completely, protein particles were distributed in the CAPP films. To determine
whether the heterogeneous distribution affected release, the lysozyme-loaded films were
tested in two orientations (protein side up and protein side down) within the polystyrene
well.
Supernatants were analyzed using UV spectroscopy (Powerwave HT, Biotek) to
determine the concentration of metronidazole (318 nm) and doxycycline (350 nm). High
performance liquid chromatography (HPLC; Shimadu Prominence) was used to measure
the concentration of ketoprofen (mobile phase of acetonitrile (60):trifluroacetic acid (TFA)
buffer (40); UV detection at 260 nm) and simvastatin (mobile phase of acetonitrile
(70):TFA buffer (30); UV detection at 240 nm). The BCA protein assay (Pierce, Rockford,
IL) was used to quantify the concentration of lysozyme.
3.2.4 Mathematical modelling
Release profiles for drugs released from the CAPP system were evaluated using
Hopfenberg’s model for controlled release from erodible slabs (Equation 1):

(1)
where Mt is the amount of drug released (mg) at time t (hours), M∞ the total amount of
drug released from the device (mg), ko the erosion constant (mg/hr/mm2), Co initial
concentration of the drug in the device (mg/mm3), a the half thickness of the slab, and n=1
for a slab.(Hopfenberg H 1976) Based on the conditions provided for the model, CAPP
devices were considered erodible slabs. Furthermore, only one side of the slab was exposed
for polymer erosion and drug release due to the presence of the polystyrene well. To
accommodate this condition of unidirectional erosion and release, the term a (half the
thickness of the slab) was replaced with 2a (total thickness of the slab in mm) in equation
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(1). The predicted release profiles were compared with the experimentally determined
cumulative release profiles.
3.2.5 Bioactivity of the released protein
Lysozyme bioactivity was measured by its ability to lyse cell walls of Micrococcus
lysodeikticus (Sigma).(Ghaderi and Carlfors 1997, Jiang, Hu et al. 2005) Lysozyme release
supernatant or standard dilutions of lysozyme in PBS were added to 0.5 mg/mL of M.
lysodeikticus, and the absorbance at 450 nm was measured at 0 and 10 minutes. The
observed and expected (obtained from the standard curve) absorbances were compared to
determine the relative bioactivity of released lysozyme.
3.2.6 Statistical analysis
Experimental data were analyzed for statistical significance by the Student’s t-test
using InStat (GraphPad Software, Inc., La Jolla, CA). Slopes of the release profiles for
different drugs as well as those obtained from mathematical modeling were analyzed by
linear regression using Graphpad Prism software.

19

3.3 Results & Discussion
3.3.1 Morphological characterization
SEM showed clear demarcation between the alternating layers of drug-loaded and
blank CAPP films along with some interlayer voids and defects that were likely created
during multilayered fabrication (Figure 3.2 A). Figure 3.2 B shows the cross-section of a
multilayered CAPP film with alternating layers of fluorescein-loaded and blank CAPP
films visualized by fluorescence microscopy. Heterogeneity in distribution was observed
on the top/side of the CAPP layer where it was attached to another CAPP layer. Figure 3.2
C shows a cross-section of a sample after 6 days of incubation at 37°C. Both fluorescence
images showed that layers loaded with fluorescein were distinctly separate from the blank
CAPP layers. Line profiling quantitatively confirmed the distinction between the
fluorescein-loaded and blank CAPP films. Line profiles obtained at three different sections
of the multilayered device showed clear separation in brightness between layers.
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Figure 3.2: Morphology of multilayered CAPP devices. (A) SEM image of the crosssection showing four CAPP films attached to each other. Fluorescent images of
multilayered CAPP devices with alternating fluorescein-loaded and blank films obtained
(B) one day after fabrication and (C) after 6 days of incubation at 37ºC. (D) Line profiles
showing the distinct difference between the fluorescein-loaded and blank layers at different
locations (shown in Figure 3.2 B).
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3.3.2 Single layer drug release profiles
Release of individual drugs (metronidazole, ketoprofen, simvastatin, doxycycline,
and lysozyme) from a single layer of CAPP showed sustained release of the drug during
the course of erosion (8-10 hours) reflecting near zero-order kinetics (Figure 3.3 A and 3.3
B). The total amount of drug released from the CAPP films corresponded to the amount
of drug loaded in the CAPP films. For example, 5 wt% of metronidazole and ketoprofen
was loaded in the CAPP films, which resulted in 1 mg of drug in each sample. The
cumulative release profile showed that, on average, 97% of the metronidazole and 89% of
ketoprofen loaded in the CAPP films were detected (Figure 3.3 A). The loading of
simvastatin and doxycycline was 2.5 wt%, resulting in 0.5 mg of drug present in each
sample. The average percentages of simvastatin and doxycycline released were 100% and
98%, respectively (Figure 3.3 B). Slopes of the release profiles for different small molecule
drugs released from single-layered CAPP films were statistically similar. The release
profiles of lysozyme-loaded CAPP films, however, differed from those of the other drugs
(Figure 3C). Approximately 60% of the protein was released either during the first 4 hours
of film erosion or during the final 4 hours, depending on which surface of lysozyme films
was exposed to PBS.
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Figure 3.3: Profiles showing release of drugs from CAPP films. (A) Cumulative release
of metronidazole and ketoprofen (5 wt% loading). (B) Cumulative release of doxycycline
and simvastatin (2.5 wt% loading). (C) Instantaneous release of lysozyme from CAPP
films with top or bottom surface exposed to PBS. Data are mean ± standard deviation
(n=3).
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3.3.3 Intermittent and sequential drug release profiles
Polymer erosion of multilayered (four-layered) CAPP devices with alternating
metronidazole-loaded and blank layers resulted in intermittent release of the same drug
(Figure 3.4 A). This release profile showed no release of drug during the initial stages of
erosion (first 10 hours) due to the presence of blank layer on top, followed by release of
metronidazole from the second CAPP layer (approximately 10-40 hours). The third (blank)
layer delayed release of metronidazole from the fourth layer, while metronidazole from the
final (bottom) layer of the device was released during the last stages (last 40 hours) of
erosion.
Figure 3.4 B shows release profiles for three-layered devices with metronidazoleand ketoprofen-loaded layers separated by an intermediate blank film eroded in 4 mL of
PBS. Based on design of the device, metronidazole was released during the first 20-25
hours of device erosion. The blank layer delayed the next phase of release, which involved
release of ketoprofen during the final stages of device erosion (last 40-50 hours). When the
same type of device was eroded in 2 mL of PBS, the total erosion time was around 155
hours compared to only 77 hours observed for 4 mL PBS (Figure 3.4 C). Even though the
device eroded more slowly when the amount of medium (PBS) was reduced, sequential
drug release was still achieved. Metronidazole was released during the first 40 hours of
device erosion followed by a small delay in the release of ketoprofen due to the presence
of the blank layer; ketoprofen was again released during the last 100 hours of the device
erosion.
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Figure 3.4: Instantaneous drug release profiles for multilayered CAPP devices. (A)
Intermittent release of metronidazole (blank-metronidazole-blank-metronidazole) during
erosion in 4 mL of PBS. Sequential release of metronidazole followed by ketoprofen
(metronidazole-blank-ketoprofen) during erosion in (B) 4 mL or (C) 2 mL of PBS. Data
are mean ± standard deviation (n=3).
Figure 3.5 A shows both empirical and predicted release of one drug
(metronidazole) from a single layer CAPP film. As for films containing metronidazole and
ketoprofen, multilayered devices with simvastatin and doxycycline eroded in 2 mL of PBS
also followed the same sequential release pattern, with a total erosion time of
approximately 160 hours (Figure 3.5 B). Simvastatin was released significantly faster
during the first 50 hours of device erosion than doxycycline was released during the last
100 hours (p<0.05), but there were no significant differences between the experimentally
measured slopes and those predicted by mathematical modeling.
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Figure 3.5: Comparison of observed and mathematically predicted cumulative release
profiles for (A) metronidazole in a single layer CAPP film and (B) simvastatin followed
by doxycycline in a three-layered film. Data are mean ± standard deviation (n=3).
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3.3.4 Loading and release efficiency
In general, 96.5% of the small molecule drugs loaded into CAPP films was
released, irrespective of the type or wt% of the drug (Figure 3.6 A). There was no
statistically significant difference between the observed and expected amount of
metronidazole and doxycycline loaded and released from the CAPP multilayer devices. In
the case of ketoprofen, 83% of the expected amount was released, and in the case of
simvastatin 90% of the expected amount was released.
3.3.5 Mass loss profiles
Figure 3.6 B shows mass loss profiles for three-layered devices eroded in 2 mL of
PBS. The profiles presented are for blank, sequential metronidazole and ketoprofen, and
sequential simvastatin and doxycycline films. Both the blank devices and the drug-loaded
devices eroded with linear mass loss profile characteristic of a zero-order system. Neither
loading nor the type of drug incorporated into the films had a significant effect on the
erosion rate.
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Figure 3.6: (A) Observed and expected amounts of drugs released from multilayered
CAPP devices. (B) Mass loss profiles for multilayered devices with blank layers (blank),
layers loaded with metronidazole and ketoprofen (metro and keto), or layers loaded with
simvastatin and doxycycline (sim and doxy) degraded in 2 mL of PBS.
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3.3.6 Bioactivity of released protein
Figure 3.7 shows the bioactivity of lysozyme in release supernatants during the
final 6 hours (time points when lysozyme release occurred) of film erosion. Results showed
that, on an average, lysozyme released from the CAPP films retained 57% of the expected
bioactivity.

Figure 3.7: Retention of lysozyme bioactivity following release from CAPP films. Data
are mean ± standard deviation (n=3).
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3.4 Discussion
The main aim of this research was to develop a CAPP film-based system that will
serve as a platform for delivery of different types of drugs, suitable for treatment of a broad
range of disease conditions. These multilayered devices may also be adapted for delivery
of more than one type of biomolecule for tissue engineering applications.
The two polymers used for the association polymer, CAP and Pluronic F-127, form
intermolecular hydrogen bonds in aprotic solvents, such as acetone, used during
fabrication. In this case, carboxylic acid groups in CAP act as proton donors, and the ether
sites in the non-ionic surfactant Pluronic F127 form the proton acceptors.(Gates, Grad et
al. 1994) When the CAPP system is exposed to physiological conditions, deprotonation
occurs and leads to dissolution of the CAPP into its CAP and Pluronic components. This
type of mechanism results in erosion-based, sustained release of drugs.(Gates, Grad et al.
1994, Raiche and Puleo 2003, Jeon, Thomas et al. 2007) CAP is commonly used as an
enteric coating on tablets(Roxin, Karlsson et al. 1998), and Pluronic, an amphiphilic
triblock copolymer, has been widely used for drug delivery purposes and as a surfactant.
(Kabanov, Batrakova et al. 2002) In vivo studies have been performed with the CAPP
association polymer system without any adverse effects.(Jeon, Piepgrass et al. 2008)
The CAPP polymer system has been used in the form of microspheres(Jeon,
Thomas et al. 2007) and single-layered films(Xu and Lee 1993) for zero-order release of
different drugs, but the present research focused on its use in multilayered devices for
delivery more than one type of drug. CAPP in the form of films is more appropriate for
this application, as it suits the design of multilayered devices for sequential delivery of
multiple drugs. The fabrication of the CAPP films involves a relatively simple solvent
evaporation technique compared with other fabrication processes, such as melt processing
and injection molding, needed for other surface-eroding polymers. Fabrication of the
multilayered devices involved adhering individual CAPP films using acetone as a solvent
for plasticizing the surface of the CAPP films without altering the bulk properties of the
film. This simple technique without the use of potentially harsh processing conditions, such
high temperature and pressure, reduces the chances of small molecule drugs losing
bioactivity during the fabrication process. Limitations of these CAPP films include the
non-uniform distribution of hydrophilic molecules, such as proteins and lack of mechanical
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flexibility of the films which is being addressed by inclusion of a plasticizing agent during
the fabrication process.
3.4.1 Morphological characterization
SEM and fluorescence microscopy were used to characterize the morphological
properties of the multilayered CAPP device. SEM images of the cross-section of a fourlayered device showed demarcation between the CAPP layers, indicating the separation
between the drug-loaded and blank layers. This type of separation between the layers was
necessary to maintain the layer-based design of the device and enable sequential drug
release. Cross-sectional images also showed that the small volume of solvent applied to
bond layers dissolved only the surface of the films and did not affect the internal portions
of the CAPP films.
Further characterization using fluorescence imaging showed clear distinction
between the fluorescent and blank layers.

Both qualitatively and quantitatively,

fluorescence was not observed in the blank layers, which confirmed that there was no
diffusion of fluorescein from loaded to unloaded layers during fabrication. An absence of
interlayer diffusion even during incubation (“aging”) at 37°C for six days was confirmed
by the distinct separation of fluorescein-loaded and blank layers
3.4.2 Single layer drug release profiles
As indicated previously, the primary aim of this research was to fabricate a drug
delivery device that serves as a platform for delivery of wide spectrum of drugs in a
specified sequential order. For this purpose, some of the most commonly used drug types,
such as antibiotics (metronidazole and doxycycline), anti-inflammatory agents
(ketoprofen), and a potentially osteogenic small molecule drug (simvastatin), along with a
model protein (lysozyme) were chosen, and their loading and release were studied. All the
CAPP films with drugs were inserted into a polystyrene well to aid unidirectional polymer
erosion. Results for the drugs investigated in this study showcase the ability of the CAPP
system to serve as delivery platform for a variety of biomolecules.
Except for lysozyme, the other four drugs that were loaded and released are
currently used for treatment in patients. Metronidazole is effective against most Gramnegative and Gram-positive anaerobic bacteria and a wide variety of protozoans.(Freeman,
Klutman et al. 1997) Doxycycline is one of the commonly prescribed tetracycline
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antibiotics that are effective against variety of infectious agents.(Cunha, Domenico et al.
2000) In addition, it also possesses bone anti-resorptive properties.(Vernillo and Rifkin
1998) Ketoprofen, which is commonly used for treatment of arthritis(Veys 1991) and in
dentistry,(Johnny G 1988) is a phenylproprionic acid derivative with analgesic, antiinflammatory, and antipyretic properties. The fourth small molecule drug used in this study
was simvastatin, which is widely used for controlling high cholesterol level.(Todd and Goa
1990) Importantly, however, simvastatin has the ability to stimulate bone formation via
enhanced expression of bone morphogenetic protein 2 (BMP-2).(Chen, Sun et al. 2010)
All four drugs were released in a sustained manner from the CAPP films and
followed zero-order release kinetics. In vitro release results for the single layer CAPP films
were statistically comparable to predictions from Hopfenberg’s model developed to predict
drug release from a slab.(Hopfenberg H 1976) Irrespective of the type of drug or the
amount of drug that was loaded, similar release rates were measured, and nearly all of the
drug was accounted for during the experiments. As a nonionic surfactant, the Pluronic F127 component of this association polymer increases the solubilizing power of the
system.(Xu and Lee 1993) This property allows a wide range of dosages to be achieved.
The model protein that was loaded into and released from CAPP films was
lysozyme. Being hydrophilic, lysozyme did not dissolve completely in acetone during the
fabrication process. To determine the effect of the non-uniformly distributed lysozyme
particles on the release profiles, lysozyme-loaded CAPP films were eroded in two different
orientations. When the film surface that was in contact with the Teflon dish (bottom
surface, where the undissolved lysozyme settled during fabrication) was attached face
down in the impermeable well, the top surface (with fewer lysozyme particles) eroded
initially, and protein was predominantly released during the final stages of the film erosion.
When the film surface that was exposed to the atmosphere (top surface) during film
fabrication faced the polystyrene, release of lysozyme occurred during the initial stages of
films erosion. These release profiles further confirm that release of lysozyme occurred by
surface erosion of polymer, because lysozyme was released only when the part of the
polymer film with high concentration of lysozyme was exposed.
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3.4.3 Intermittent and sequential release of drugs
Erosion of multilayered devices in vitro resulted in successful release of drugs in
both intermittent and sequential manners. These multilayered devices also had a
polystyrene backing layer for unidirectional polymer erosion and drug release. Further
research is being conducted to replace the non-degradable polystyrene with a
biodegradable backing material suitable for in vivo implantation.
Intermittent release of the antibiotic metronidazole was achieved using an
intermediate blank CAPP layer. Similarly, sequential release of an antibiotic,
metronidazole, and an anti-inflammatory agent, ketoprofen, was also demonstrated by
placing a blank CAPP layer between drug-loaded layers. When incubated in a smaller
volume of PBS, the same devices with metronidazole and ketoprofen eroded at a slower
rate. These findings show the effect that the sink has on device erosion and the consequent
release profile. In both release studies, the interval at which the samples were collected was
the same (every 8-10 hours). The release byproducts generated during erosion of CAPP
might have saturated the smaller volume of release medium and thereby prevented
(slowed) further polymer erosion. When a larger volume of release medium was used,
saturation with erosion byproducts would have occurred relatively slower, thereby
resulting in faster erosion. In spite of the change in erosion rate, sequential release of
metronidazole followed by the release of ketoprofen was not altered. In the multilayered
devices, release of the second drug occurred in a relatively more sustained manner when
compared to the first drug. When multilayered devices were eroded in 4 mL of PBS, the
first drug was released within 20 hours, and the second drug was released over the last 50
hours. This can be explained by the cylindrical polystyrene wells in which the layers were
inserted. As CAPP eroded, PBS was retained within the well, and the reduced circulation
of medium near the final layer resulted in relatively slower erosion and drug release. With
only 2 mL of PBS, the first drug was released within 40 hours, and the second drug was
released over the last 100 hours. In this case, the combined effects of the reduced sink
conditions and reduced mixing within the wells further slowed erosion, but the total amount
of drug released was not significantly affected. Mass balance calculations again showed
comparable expected and observed drug amounts loaded and released. Hopfenberg’s
equation was also suitable for modeling sequential release of more than one drug from the
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multilayer CAPP device. The predicted profiles also showed that the rate of release of the
first drug was approximately twice as fast as that for the second drug. The predicted and
experimentally measured release profiles were statistically similar for both the single layer
and multilayered devices, indicating the suitability of this particular model for the present
delivery system. This model for predicting the release profiles from CAPP devices would
be helpful for further design of advanced multilayered devices.
Mass loss profiles showed that CAPP devices, irrespective of the type of drugs
loaded, followed a surface-erosion pattern. As such, the duration of the drug release as well
as the time interval between the release peaks of the same or different drugs can be
increased or decreased by altering the thickness of the blank CAPP films. Overall, the type
and amount of drug loaded in the CAPP films can be altered to achieve a desired
intermittent or sequential release using this multilayered system.
3.4.4 Bioactivity of released protein
Because proteins are more unstable compared to small molecule drugs, initial
bioactivity testing was conducted for only the protein that was released from the CAPP
films. Results showed that lysozyme lost approximately 40% of its activity during loading
and delivery. Other commonly used bioerodible/biodegradable delivery systems, such as
poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene gycol) (PEG), also result in loss
of protein activity by aggregation, hydrolytic degradation, and chemical modification
during the necessary manufacturing process, which can involve heating, pH changes, shear
forces, organic solvents, drying and others.(Gombotz and Pettit 1995) With the CAPP
delivery system, however, the amount of protein loaded can be easily altered, and
excipients may enhance preservation of bioactivity.
The present studies have shown that CAPP film-based devices can be used to
deliver a wide variety of drugs and can be used to achieve sequential delivery of multiple
drugs. These advantages will be helpful for customizing devices different applications. For
example, some bacterial infections, which might involve more than one type of
microorganism, require combination of antibiotics for treatment(Griffiths, Ayob et al.) to
eliminate

the

infection

and

reduce

the

potential

for

developing

antibiotic

resistance.(Dowling 1957) The ability of this CAPP system to sequentially deliver antiinflammatory agents with other drugs creates the possibility of inflammation control and
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pain management during wound healing. The system may also be useful for delivery of
multiple growth factors for tissue engineering. A growing body of research suggests the
importance of more than one growth factor for regeneration of tissues, such as bone,(Jeon
and Puleo 2008) (Raschke, Wildemann et al. 2002) (Yilgor, Tuzlakoglu et al. 2009) blood
vessels,(Richardson, Peters et al. 2001) and cartilage.(Elisseeff, McIntosh et al. 2001)
(Fukumoto, Sperling et al. 2003)
There have been several attempts towards the delivery of multiple growth
factors.(Chen, Chen et al.) Most of these approaches, however, have been successful for
simultaneous delivery.(Lynch, de Castilla et al. 1991, Schmidmaier, Wildemann et al.
2002, Nevins, Camelo et al. 2003, Simmons, Alsberg et al. 2004, Dogan, Gumusderelioglu
et al. 2005, Peattie, Rieke et al. 2006, Riley, Fuegy et al. 2006, Nillesen, Geutjes et al.
2007, Patel, Young et al. 2008, Chen, Chen et al. 2009, Young, Patel et al. 2009, Borselli,
Storrie et al.)

Temporally controlled release has been obtained by other strategies,

including fabrication scaffolds and/or microspheres consisting of one or more polymers
each loaded with a different drug, e.g., PLGA in combination with gelatin hydrogels,
poly(propylene fumarate), poly(4-vinyl pyridine), alginic acid, cellulose acetate.(Chen,
Silva et al. 2007, Buket Basmanav, Kose et al. 2008, Jaklenec, Hinckfuss et al. 2008,
Kempen, Lu et al. 2009, Tengood, Kovach et al. 2010) The system presented in this paper
was composed of a single association polymer system in the form of multilayered films,
which simplifies the fabrication process and eases loading of wide variety of drugs to
obtain localized delivery of multiple drugs in a required temporal sequence.

3.5 Conclusion
The easy to fabricate CAPP association polymer can be used to achieve zero-order release
of a wide variety of drugs. As such, this system can serve as a general platform for
localized, controlled drug delivery to treat several disease conditions. Different release
profiles can be designed, including sustained release of one drug, intermittent release of a
drug, or sequential release of multiple drugs. This system could be used for applications
that require delivery of more than one type drug in a predetermined temporal sequence.
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Chapter 4 Design of a Multiple Drug Delivery System Directed at Periodontitis

4.1 Introduction
Periodontitis is one of the most common inflammatory diseases and is a leading
cause of tooth loss in adults (Brown, Oliver et al. 1989, Albandar and Kingman 1999). It
is also related to systemic disorders, such as coronary artery disease, stroke, and diabetes
(Soskolne and Klinger 2001, Chen, Chen et al. 2009). In the initial stages of periodontitis,
the onset of bacterial infection is followed by the host response of active and progressive
inflammation, leading to resorption and loss of tissue (Dionne and Berthold 2001). When
periodontitis is well-established, effective therapeutic and surgical intervention is required
for the removal of bacterial plaque, control of inflammation, and inhibition of progressive
bone loss with subsequent complete repair and regeneration of functional periodontium
(Chen, Chen et al. 2009). One of the most common methods for treating chronic
periodontitis involves mechanical debridement of periodontal pockets by scaling and root
planning along with effective plaque control to eliminate bacterial infection (Etienne
2003). Subsequent periodontal regenerative procedures are time-consuming and
financially demanding (Polimeni, Xiropaidis et al. 2006), and currently there is no ideal
therapeutic approach to completely cure periodontitis and achieve predictable tissue
regeneration (Chen, Chen et al. 2009). Because the progression of periodontitis involves a
complex, sequential relationship between infection, inflammation, and tissue loss (Caton,
Ciancio et al. 2000), treatment might be improved by controlled release of multiple
biologically active agents in an appropriate sequence (Cochran D L. (2003)).
Vyas et al. reviewed controlled drug delivery systems that have been employed for
treating periodontal diseases (Vyas, Sihorkar et al. 2000). Some approaches involved
localized delivery of antibiotics for elimination of bacterial infection (SchwachAbdellaoui, Vivien-Castioni et al. 2000, Etienne 2003), while others have addressed
inflammation (Queiroz-Junior, Pacheco et al. 2009, Srinivas, Medaiah et al. 2011) or bone
resorption (Binderman, Adut et al. 2000). Periodontal regeneration has also been attempted
using local delivery of osteogenic agents (King, King et al. 1998, Selvig, Sorensen et al.
2002, Yazawa, Zimmermann et al. 2005, Seto, Ohba et al. 2008). None of these methods,
however, addressed all aspects of the disease to achieve comprehensive treatment.
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The present research was aimed at developing an “all-encompassing”, multiple
drug delivery system capable of delivering antibacterial, anti-inflammatory, antiresorptive, and osteogenic agents in the appropriate sequence for potential treatment of
periodontitis. Figure 4.1 shows a schematic representation of the order in which the drugs
will be delivered at different stages based on pathogenesis of the disease.

Figure 4.1: Proposed sequential drug delivery based on the pathogenesis of periodontal
disease.
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4.2 Materials & Methods
4.2.1 Fabrication of multilayered devices
Devices were fabricated using a surface-eroding association polymer system
(CAPP) comprising cellulose acetate phthalate (CAP) (Sigma-Aldrich, St. Louis, MO) and
Pluronic F-127 (P) (Sigma-Aldrich) (Xu and Lee 1993, Raiche and Puleo 2003). CAPP
films, prepared by a solvent evaporation technique, were used to fabricate the multilayer
devices. CAP and Pluronic F-127 were mixed together in the weight ratio of 70:30,
respectively, and dissolved in acetone to obtain an 8% polymer solution. The drug of
interest (5 wt %) was added to the acetone-polymer solution and mixed thoroughly until
the drug was completely dissolved. The drug-polymer solution was poured in a Teflon dish
and stored at 4ºC for 24 hours for slow evaporation of the solvent. Blank CAPP films were
prepared in the same way but without the addition of drugs. For this study, CAPP films
were loaded with metronidazole (Sigma-Aldrich), ketoprofen (Sigma-Aldrich),
doxycycline (Sigma-Aldrich), or simvastatin (Haorui Pharma-Chem, Inc., Edison, NJ).
Samples with diameter of around 6 mm and thickness of 0.5 mm were punched out of the
CAPP films. The drug-loaded discs were arranged in the desired sequence with alternating
layers of blank CAPP films (Figure 4.2).
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(A)

(B)

(C)
Figure 4.2: Schematic representation of how multilayered CAPP devices were fabricated.
(A) 7-layer device with one blank layer between drug layers. (B) 10-layer device with two
blank layers between drug layers. (C) 10-layer device with PSA layer between the blank
layers. Note: Illustration is not to scale.
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The stack of the CAPP films was bonded together by compressing them after
acetone had been applied between the layers. The multilayered device was then coated with
poly(sebacic acid) (diacetoxy-terminated; PSA; Sigma-Aldrich), which acted as a barrier
to enable unidirectional erosion and drug release. Blank (drug-free) multilayered devices
were used for comparison. Three different device designs were investigated for increasing
the duration of erosion and release. In addition to the single CAPP blank layers, either two
blank layers were used or a thin PSA layer was included between the blank layers.
4.2.2 Mass loss and drug release
The multilayered devices were eroded in phosphate-buffered saline (PBS), pH 7.4,
during incubation at 37ºC with gentle shaking. After collecting the supernatants at regular
time intervals, the samples were weighed and then fresh PBS was added. The measured
mass of the samples was used to construct the mass loss profiles of the multilayered CAPP
devices. Collected supernatants were used to determine the amount of metronidazole,
ketoprofen, doxycycline, and simvastatin using high performance liquid chromatography
(HPLC; Shimadzu Prominence). For measuring the concentration of ketoprofen, an
isocratic mobile phase composed of acetonitrile (60%) and 0.1% trifluroacetic acid (TFA)
in DI (deionized) water (40%) was used with UV detection at 260 nm, and for simvastatin,
the isocratic mobile phase was acetonitrile (70%) and 0.1% TFA in DI water (30%) with
UV detection at 240 nm. A gradient mobile phase with acetonitrile and 0.1% TFA in DI
water was developed for measuring the concentration of metronidazole and doxycycline
with UV detection at 318 and 350 nm, respectively.
4.2.3 Mathematical modeling
Profiles of drugs released from the multilayered CAPP device weres evaluated
using Hopfenberg’s model for controlled release from erodible slabs (Eq. 1):

𝑀𝑀𝑡𝑡

𝑀𝑀∞

= 1 − �1 −

𝑘𝑘0 𝑡𝑡

𝐶𝐶0 𝑎𝑎

�

(1)

where Mt is the amount of drug released (mg) at time t (hours), M ͚ the total amount of
drug released from the device (mg), ko the erosion constant (mg/hr/mm2), Co initial
concentration of the drug in the device (mg/mm3), a the half thickness of the slab, and n=1
for a slab (Hopfenberg H 1976). Because only one side of the CAPP layer (slab) was
exposed for polymer erosion and drug release due to the presence of the PSA barrier, the
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term a (half the thickness of the slab) was replaced with 2a (total thickness of the slab in
mm) in equation (1). The release profiles predicted using this mathematical model were
compared with the experimentally-obtained cumulative release profiles of the four drugs.
4.2.4 Bioactivity
Bioactivity of released metronidazole or ketoprofen was measured to assess effects
of encapsulation and release. The Kirby-Bauer assay was performed to test the antibacterial
activity of metronidazole. An aliquot of Porphyromonas gingivalis (FDC381) (P.
gingivalis) culture was uniformly spread on blood agar plates using polystyrene beads.
Release supernatant (7 µL) containing metronidazole was added to 7 mm diameter filter
paper discs and placed on the P. gingivalis-inoculated plates. After 24 hour incubation
under anaerobic conditions, the plates were imaged, and the area of inhibition (clear zone)
around the filter papers was measured using ImageJ software. Results from the release
supernatants were compared to the clear zones obtained using serial dilutions of fresh
antibiotic to determine the percent bioactivity. A cyclooxygenase (COX) inhibitor assay
kit (Cayman Chemical Company, Ann Arbor, MI) was used to determine the bioactivity of
the ketoprofen released from the CAPP films. Activity against COX-1 enzyme was
measured using the manufacturer’s protocol. As for metronidazole, COX inhibition by the
release supernatants was compared with that of freshly prepared standard dilutions of
ketoprofen to determine the percent bioactivity.
4.2.5 Statistical analysis
Mass loss and drug release profiles, both experimental and predicted from
mathematical modeling, were analyzed by linear regression using GraphPad Prism
software (La Jolla, CA). Statistically significant differences between the bioactivity of the
“fresh” drugs and the those released from the CAPP films were determined using the
Student’s t-test (InStat, GraphPad Software).
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4.3 Results
4.3.1 Mass loss profiles
Figure 4.3 shows the mass loss profiles for the multilayered CAPP devices when
eroded in PBS. Both the control (blank) devices without drug and the drug-loaded CAPP
devices followed similar linear erosion profiles (Figure 4.3 A). There was no statistically
significant difference between the slopes of the mass loss curves during the course of the
study. Mass loss profiles of the multilayered devices with single blank layers, two blank
layers, and with PSA blank layers are shown in Figure 4.3 B. Comparison of the slopes of
the mass loss curves also showed that there were no statistically significant differences in
the rate of erosion between the different types of devices. The y-intercept of the lines
indicates the average initial mass of the different devices. On average, mass loss occurred
at a rate of 0.08 mg/mm2/hour when sink conditions were maintained by replacing PBS at
regular time intervals.
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Figure 4.3: Mass loss profiles for: (A) 7-layered blank and drug-loaded CAPP devices;
(B) Drug-loaded devices with one blank layer, two blank layers, or two blank layers along
with PSA between the drug layers. Data are mean ± standard deviation (n=3).
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4.3.2 Drug release profiles
Figure 4.4 A shows the instantaneous profiles for four drugs released from the
multilayered delivery system. Because metronidazole was loaded in the layer initially
exposed when erosion started, it was the first drug released within 15-20 hours of
incubation in PBS. This was followed by release of the anti-inflammatory drug ketoprofen
during the course of further device erosion. Ketoprofen release finished midway (around
40 hours) through the total device erosion time (70-80 hours). The third drug released from
the system was doxycycline, which started around 25 hour and lasted through 50 hours.
The last drug, simvastatin, was released during the final stages of device erosion (50-80
hours).
The multilayered devices fabricated with two blank layers, instead of just one,
between the drug-loaded layers showed similar sequential release of four drugs (Figure 4.4
B). With two blank layers, however, the separation between the drug release peaks was
more distinct, and the erosion time of the whole device was increased to 120 hours. In this
case, the first drug, metronidazole, was released within the first 25 hours followed by the
release of ketoprofen through 60 hours, which was half the erosion time of the device.
Release of the third drug, doxycycline, started at around 40 hours and lasted until 100
hours, and this was followed by release of simvastatin through complete erosion of the
devices at 120 hours.
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Figure 4.4: Fractional instantaneous release profiles of four drugs from: (A) 7-layer
devices with single blank layers; (B) 10-layer devices with two blank layers; and (C) 10layer devices with double blank layers plus PSA. Data are mean ± standard deviation
(n=3).
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The use of the PSA layers between the CAPP blank layers further increased the
erosion time of the device to 160 hours. Release of metronidazole occurred within the first
25 hours, as in the case of the other two device types. But the presence of PSA layers before
the other drug layers slowed erosion and extended the release periods of ketoprofen,
doxycycline, and simvastatin to 20-80, 50-100, and 90-160 hours, respectively. The times
at which the peaks were observed for all four drugs in the three different device types are
given in Table 4.1.
Table 4.1: Time of metronidazole, ketoprofen, doxycycline, and simvastatin peaks for the
three types of devices fabricated and tested.
Device
type

Metronidazole
(hour)

Ketoprofen
(hour)

Doxycycline
(hour)

Simvastatin
(hour)

Total
erosion
time
(hours)

One blank

9

24

38

53

78

9

36

70

100

116

10

38

74

103

161

Two
blanks
PSA with
two blanks

4.3.3 Mathematical modeling and mass balance
In vitro release of four drugs from the multilayered devices was compared to the
profiles predicted using Hopfenberg’s model. Figure 4.5 shows representative results for
the double blank layer devices. The predicted release profiles were similar to those
measured for sequential release of the four drugs from the multilayered CAPP devices.
Linear regression showed that there were no statistically significant differences between
the slopes of the predicted and experimental drug release profiles. The measured amounts
of drugs released were not significantly different from the expected amounts.
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Figure 4.5: Cumulative drug release from double blank layer devices along with
mathematical modeling.
4.3.4 Bioactivity
Figure 4.6 shows the bioactivity of the metronidazole supernatants at 1, 3, and 5
hours of release from single-layered CAPP films as measured by the ability to kill P.
gingivalis. The results of the Kirby-Bauer assay showed that the observed area of inhibition
caused by the metronidazole supernatants from all the release/erosion supernatants was
about 10% higher than that expected from fresh antibiotic solutions of the same
concentration. Even though the observed area of inhibition was higher than expected,
statistical analysis showed that the difference was statistically significant at only the 5 hour
time point (p = 0.0152). Release supernatants from blank CAPP films, which were used
as controls, did not produce any clear area (not shown).
By measuring inhibition of COX-1 enzyme activity, ketoprofen in release
supernatants was also found to have retained its bioactivity (Figure 6). Even though the
assay results showed that the ketoprofen from the release supernatant had more than 100%
bioactivity retention, about 120% on an average, statistical analysis showed that there were
no significant differences.
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Figure 4.6: Percentage of bioactivity retained by metronidazole and ketoprofen released
from CAPP films. Data are mean ± standard deviation (n=3).
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4.4 Discussion
The complexity of periodontal pathogenesis necessitates use of more than one type
of drug for complete treatment of the condition. For this purpose, a localized delivery
system capable of releasing multiple drugs in a sequential order would be ideal. Chen et al.
(Chen and Jin 2010) and Santo et al. (Santo, Gomes et al. 2013) have given a detailed
account of current research on multiple drug delivery systems for tissue engineering. The
majority of these multiple drug delivery systems were designed for release of more than
one type of drug simultaneously (Lynch, de Castilla et al. 1991, Simmons, Alsberg et al.
2004, Dogan, Gumusderelioglu et al. 2005, Peattie, Rieke et al. 2006, Patel, Young et al.
2008, Chen, Chen et al. 2009, Borselli, Storrie et al. 2010) or sequential release of more
than one type of drug by using composite devices comprising more than one polymer
(Chen, Silva et al. 2007, Buket Basmanav, Kose et al. 2008, Jaklenec, Hinckfuss et al.
2008, Kempen, Lu et al. 2009, Tengood, Kovach et al. 2010). The multilayered delivery
devices designed for the present research using a single association polymer system
successfully released four different drugs in the desired temporal sequence for potential
treatment of periodontitis. The sequence in which these four drugs are delivered is of
critical importance for the treatment of the disease. For example, administration of an
osteogenic agent before elimination of the bacterial infection and inflammation would not
be as effective for tissue regeneration.
Delivery devices based on the CAPP association polymer system have been used
for drug release both in the form of films and microspheres (Gates, Grad et al. 1994, Jeon,
Piepgrass et al. 2008). For the present research, the physical form of films was selected for
designing a system for sequential drug release. Previous research demonstrated that CAPP
films can deliver drugs in a near-zero-order fashion(Sharath C. Sundararaj 2013). In
agreement, the mass loss profile followed a linear pattern with the mass loss occurring at a
rate of 2.5 mg/hour, suggesting surface erosion and drug release. Use of the surface-eroding
polyanhydride poly(sebacic acid), which erodes more slowly than does CAPP, as a barrier
layer limited erosion to only one surface and, therefore, unidirectional erosion and drug
release.
Selection of the appropriate drugs is also an important factor for successful therapy.
The first step in the treatment of periodontitis involves elimination of the bacterial
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infection. The initial stages of wound management are critical for repair and regeneration
of periodontal tissues, because the innate regenerative potential of the periodontium is
dependent on wound stability (Polimeni, Xiropaidis et al. 2006). The localized delivery of
various antimicrobial agents for treatment of chronic periodontitis and its advantages have
been discussed by Etienne (Etienne 2003). Of the various antimicrobial agents used,
including tetracycline, chlorhexidine, doxycycline, and minocycline (Etienne 2003),
metronidazole was chosen for this research because it is one of the most commonly used
antibiotics against periodontal pathogens. Metronidazole concentrations achieved by
systemic administration might not be effective against biofilm-associated P. gingivalis
(Wright, Ellen et al. 1997), however, which further increases the need for localized
antibiotic delivery for the treatment of chronic periodontal conditions. Porphyromonas
gingivalis is a pathogenic bacterium commonly associated with periodontal infections
(Tribble, Lamont et al. 2007, Japoni, Vasin et al. 2011). Metronidazole has been shown to
significantly reduce P. gingivalis infection compared to other antibiotics in vitro (Eick and
Pfister 2004), and it is effective against different strains (Larsen 2002). Localized delivery
of metronidazole has been achieved in the form of gels for treatment (Sato, Fonseca et al.
2008), and studies have shown that metronidazole can readily attain minimum inhibitory
concentrations in gingival tissue and crevicular fluid (Van Oosten, Notten et al. 1986,
Tenenbaum, Cuisinier et al. 1993). Besides gels, metronidazole has also been loaded and
released using CAPP films by Gates et al. (Gates, Grad et al. 1994) and by the authors
(Sharath C. Sundararaj 2013). The effectiveness of metronidazole as an antimicrobial agent
against periodontal pathogens and its successful localized delivery using CAPP films
makes it an appropriate option for the first drug to be delivered for the treatment of
periodontitis.
The bacterial infection associated with periodontitis results in an exuberant host
response, with chronic inflammation leading to the loss of soft tissue and resorption of the
alveolar bone (Williams 1990). The persistence of inflammation will affect the
regenerative process even if growth factors or other osteogenic agents are provided (Caton,
Ciancio et al. 2000). Consequently, the inflammatory response must be controlled before
attempting to prevent bone resorption and aid regeneration. The present CAPP system was
capable of releasing the anti-inflammatory drug ketoprofen before delivering antiresorptive
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and osteogenic agents. Ketoprofen has been successfully used in the treatment of
periodontitis (Paquette, Fiorellini et al. 1997, Salvi and Lang 2005). Both systemic and
topical administration of ketoprofen in the form of gels was effective in reducing
prostaglandin levels in gingival crevicular fluid in adult periodontal patients, which thus
aided inhibition of disease progression (Lawrence, Paquette et al. 1998, Paquette,
Lawrence et al. 2000). Both metronidazole and ketoprofen retained essentially 100% of
their bioactivity, which shows that the loading of drugs in the CAPP films and their
subsequent release did not adversely affect the drugs.
After ketoprofen, doxycycline was released from the CAPP delivery system.
Doxycycline, a tetracycline derivative, has significant anti-matrix metalloproteinase
activity and also inhibits osteoclast development, structure, and function (Vernillo and
Rifkin 1998). Furthermore, doxycycline also has antimicrobial properties and has been
shown to be effective against P. gingivalis (Larsen 2002). Llindhe et al. showed the
effectiveness of locally delivered tetracycline using hollow fibers in periodontal pockets
for the elimination or reduction of clinical symptoms of periodontitis (Llindhe, Heijl et al.
1979). These factors make doxycycline an appropriate third drug released to inhibit tissue
loss. The antimicrobial properties of doxycycline along with metronidazole which was
delivered first, provide continuous protection against bacteria at the site of repair and
regeneration. In the case of severe bacterial infection, a combination of antibiotics might
be more effective for periodontal treatment (Griffiths, Ayob et al. 2011), and this type of
multiple antibiotic delivery can be readily achieved using this CAPP system.
Simvastatin was the final drug released from the CAPP system. Beside its common
use for cholesterol control (Todd and Goa 1990), simvastatin serves as an osteogenic agent
(Chen, Sun et al. 2010). Apart from aiding general bone regeneration by increasing the
expression of BMP-2 (Mundy, Garrett et al. 1999), simvastatin has been specifically used
for periodontal regeneration (Pradeep and Thorat 2010). Simvastatin is a cost-effective
option when compared to BMP-2, and topical administration of simvastatin has the
potential to effectively recover alveolar bone loss (Seto, Ohba et al. 2008). Simvastatin has
been shown to have a positive effect on the periodontal ligament cells (Yazawa,
Zimmermann et al. 2005), which have the capacity to regenerate the periodontal attachment
(Karring, Nyman et al. 1993). Other studies have shown that simvastatin inhibits
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inflammation and encourages angiogenesis, which might have further positive effects on
bone formation (Edwards and Spector 2002). Simvastatin has been loaded into and released
from CAPP microspheres m compressed in the form of films for in vivo bone regeneration
(Jeon, Piepgrass et al. 2008). Along with its effectiveness in overall periodontal
regeneration, prior knowledge on delivery of simvastatin using CAPP system makes it a
suitable final drug to be released from this multilayered CAPP delivery system.
Two main advantages of this system include: 1) the relative ease with which the
CAPP films can be fabricated using the solvent evaporation technique and 2) the capability
of the devices to release a variety of bioactive drugs in a sequential manner. The dose of
drugs loaded in the CAPP films can be altered based on the severity of the condition and
the type of drug used. The time of drug release can also be controlled by altering the
thickness of the layers of CAPP films. Use of two blank layers instead of one resulted in
more distinct separation of drug release peaks and also increased the total erosion time of
the devices, in spite of slight overlapping that was observed between the adjacent drug
release peaks. The use of approximately 300 µm thick PSA layers between the CAPP blank
layers further increased the total erosion time of the device by approximately a factor of
two in comparison with the devices with single blank layers, with only a slight increase in
the overall thickness. Thus, the PSA layers can be increased in thickness or they can replace
the blank CAPP layers completely to achieve an even longer erosion time, depending on
the treatment requirements. Adjustments in the device design make it possible to achieve
different erosion times as well as different release times for the drugs. This type of
versatility will be critical in designing devices based on the specificity of disease
conditions.

4.5 Conclusions
The multilayered, bioerodible CAPP delivery system was successful in releasing
four different drugs in a predetermined temporal sequence based on the pathogenesis of
periodontitis. This device serves as an initial step in the development of multiple drug
delivery systems for use against periodontitis or other complex disease condition, which
ideally will intervene at different stages of the disease to provide a more comprehensive
treatment for the condition.
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Chapter 5

Comparison of In vitro and In vivo Sequential Drug Release

5.1 Introduction
The transition of a polymer-based drug delivery device from in vitro studies to in
vivo testing is an important step in characterization of the device properties and
performance. There is a vast amount of reviews available on the release of drug molecules
from polymeric devices in vitro (Langer and Chasin 1990, Schacht 1990, Jain, Yenet Ayen
et al. 2011), most of these in vivo studies have been logically aimed at determining
effectiveness of the drug released for treating a particular condition or regeneration of a
tissue, but not necessarily the in vivo drug release pattern. Comparatively there are few
published studies available on in vivo biomaterial degradation/erosion and drug release
profiles from these advanced devices (Schmidt, Wenz et al. 1995, Mäder, Crémmilleux et
al. 1997, Avgoustakis, Beletsi et al. 2002, Yang, Chu et al. 2002, Mittal, Sahana et al. 2007,
Zolnik and Burgess 2008, Evren ALĞIN YAPAR 2010, Mashayekhi, Mobedi et al. 2013).
Due to the highly dynamic physiological environment in which the device would
be implanted, the material would be exposed to different cell types and numerous
biomolecules (Hutmacher, Hurzeler et al. 1996), and studies have shown the effect of
enzymes on biodegradable polymers, such as poly(glycolic acid) and poly(lactic acid)
(Williams and Mort 1977, DF. 1981). The biodegradable polymers used for drug delivery
follow different degradation rates in vivo when compared to in vitro conditions (Domb and
Nudelman 1995, Hutmacher, Hurzeler et al. 1996, Tracy, Ward et al. 1999, Bolgen,
Menceloglu et al. 2005, Zolnik and Burgess 2008, Lockwood, Hergenrother et al. 2010),
and these differences would ultimately result in altered drug release profiles.
Understanding of in vivo drug release will be useful for improving the device, providing
data by which delivery can be tailored more specifically for its intended purpose in disease
treatment or tissue regeneration.
The surface-eroding CAPP association polymer system comprising cellulose
acetate phthalate (CAP) and Pluronic F-127 (P) was previously designed to deliver four
different drugs in a particular sequence aimed at treating periodontitis in a step-by-step
manner (Sharath C. Sundararaj 2013). In the present studies, after in vitro characterization
of the CAPP system by in vitro mass loss and drug release measurements, in vivo erosion
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and drug release properties were analyzed. The main aim of this research was to compare
the in vitro and in vivo behaviors of a multilayered device with the capability of sequential
release.

5.2 Materials & Methods
5.2.1 Fabrication of multilayer device
CAPP films were prepared by solvent evaporation after mixing CAP (SigmaAldrich, St. Louis, MO) and Pluronic F-127 (Sigma-Aldrich) together in the weight ratio
of 90:10, respectively. The mixture was dissolved in acetone to obtain an 8% polymer
solution followed by the addition and dissolution of the drug of interest (1 or 5 wt%) in the
polymer solution. The drug-polymer solution was poured in a Teflon dish and stored at 4ºC
for 24 hours for slow evaporation of the solvent. Blank CAPP films were prepared in the
same way but without the addition of drugs. For the present study, CAPP films were loaded
with metronidazole (Sigma-Aldrich), ketoprofen (Sigma-Aldrich), doxycycline (SigmaAldrich), or simvastatin (Haorui Pharma-Chem, Inc., Edison, NJ). Samples with diameter
of around 6 mm and thickness of 0.5 mm were punched out of the CAPP films. The drugloaded discs were arranged in the desired sequence with alternating layers of two blank
CAPP films to fabricate multilayered devices. The stack of the CAPP films was bonded
together by application of acetone between the layers. The multilayered device was then
coated with poly(sebacic acid) (diacetoxy-terminated; PSA; Sigma-Aldrich), which acted
as a barrier to enable unidirectional erosion and drug release. The completed device was
wound with 4-0 poly(glycolic acid) (PGA) (Oasis, Mettawa, IL) suture for circumferential
reinforcement followed by compression at 1,500 N using a BOSE ELF 3300 to consolidate
the layers and reduce the overall thickness of the device. Blank (drug-free) multilayered
devices were used for comparison. To increase the duration of erosion and release, a second
type of device was fabricated with a thin PSA layer included between the two blank layers.
Figure 5.1 shows a schematic representation of the process involved in fabrication of the
two types of multilayered CAPP devices. For fabrication of the devices used for, the CAPP
films and PSA were UV-sterilized for 1.5 hours, the solvents sterile-filtered, and assembly
conducted in a laminar flow hood.
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Figure 5.1: Fabrication of fast eroding and slow eroding multilayer device using
metronidazole, ketoprofen, doxycycline and simvastatin loaded CAPP layers.
5.2.2 In vitro studies
The multilayered CAPP devices were eroded in phosphate-buffered saline (PBS),
pH of 7.4, during incubation at 37ºC with gentle shaking. At regular time intervals, the
supernatant was collected, the mass of the samples was measured, and fresh PBS was
added. Sample masses were used to construct the mass loss profile of the multilayered
devices. Supernatants were used to determine the amount of drug (metronidazole,
ketoprofen, doxycycline, and simvastatin) using high performance liquid chromatography
(HPLC; Hitachi Primaide) equipped with a C18 column (Kinetix; Phenomenex, Torrance,
CA). For measuring the concentration of ketoprofen, an isocratic mobile phase of
acetonitrile (60%) and 0.1% trifluoracetic acid (TFA; 40%) was used with UV detection at
260 nm, and for simvastatin, the isocratic mobile phase was acetonitrile (70%) and 0.1%
TFA (30%) with UV detection at 240 nm was used. A gradient mobile phase with
acetonitrile and 0.1% TFA was developed for measuring the concentrations of
metronidazole and doxycycline with UV detection at 318 and 350 nm, respectively.

59

5.2.3 In vivo studies
All animal studies were conducted at the University of Kentucky in accordance
with a protocol approved by the Institutional Animal Care and Use Committee (IACUC).
Male Sprague-Dawley rats between the ages of 6 and 8 weeks were used. Four different
types of devices were implanted: 1) blank, 2) high drug dose (5 wt%), 3) low drug dose (1
wt%), and 4) low drug dose with PSA blank layers for longer erosion time. After
anesthetization and skin preparation, a transverse incision was made between the ears of
the animal, and the periosteum was slightly elevated to expose the calvarium. CAPP
devices were placed with the drug-releasing side facing the bone, and the incision was
sutured (Figure 5.2). Animals were euthanized at specific time points (Table 5.1), and the
devices were retrieved for analysis. Implants were cross-sectioned using a razor blade and
imaged for morphological analysis (Figure 5.3). Residual mass and thickness of the CAPP
layers present in the device were also measured. The retrieved devices were then
completely dissolved in PBS, and the solution containing dissolved drugs and CAPP was
filtered using a 0.45 µm syringe filter. This filtered solution was analyzed using same
HPLC methods as described in the in vitro drug release section to determine the residual
drug content.
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(A)

(B)

Figure 5.2: Implantation of a CAPP device over the rat calvarium. (A) Site of implantation
during the surgery and (B) after closure.

Figure 5.3: Cross-sectional images of devices retrieved following implantation for
increasing durations. (A) High dose devices, (B) low dose devices, and (C) low dose
devices with PSA blank layers.
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Table 5.1: Time points at which samples were retrieved during the course of in vivo study
(number of animals at each time point n=3)
Device type

Time points of device retrieval (days)

High dose devices

0.5

1

2

3

4

5

-

7

-

9

10

-

-

Low dose devices

-

1

2

-

4

-

6

-

8

-

10

-

-

Low dose devices with
PSA

-

1

-

3

-

5

-

-

8

-

-

12

18

Blank devices

-

-

-

3

-

-

6

-

-

9

-

-

-

5.2.4 Statistical analysis
Slopes of the in vitro and in vivo mass loss and thickness loss profiles were analyzed
by linear regression using Graphpad Prism software.
significant when p<0.05.
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Differences were considered

5.3 Results
5.3.1 In vitro mass loss profiles
Figure 5.4 shows mass loss profiles for the multilayered CAPP devices when
eroded in PBS. Both types of CAPP devices, either with two blank layers or with a PSA
layer between the two blank layers, followed similar linear erosion profiles. There was a
statistically significant difference between the slopes of the mass loss curves during the
course of the study (p<0.0001). Mass loss occurred at a faster rate for devices with just
two blank layers when compared with devices also having the PSA layer. Mass loss
occurred at a rate of 0.04 mg/mm2/hour for 90:10 CAPP layers when sink conditions were
maintained by replacing PBS at regular time intervals.
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PSA with two blanks
80
two blanks
60
40

y = -0.3484x + 99.912

20
y = -0.5054x + 97.191
0
0

50
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150
200
Time (hours)

250

300
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Figure 5.4: In vitro mass loss of 90:10 CAPP devices with two blanks (y = -1.229x +
236.35) and 90:10 CAPP devices with PSA layer between the blank layers (y = -0.8823x
+ 253).

5.3.2 In vitro drug release profiles
Figure 5.5 A shows the instantaneous profiles for four drugs released from the
multilayered delivery system with two blank layers. Because metronidazole was loaded in
the outermost layer, it was released during the first 30-40 hours of incubation in PBS. This
was followed by release of the anti-inflammatory drug ketoprofen from 40-90 hours during
63

the course of further device erosion. The third drug released from the system was
doxycycline, which started around 70 hours and lasted through 150 hours. The last drug,
simvastatin, was released during the final stages of device erosion (125-240 hours).
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(B)
Figure 5.5: Sequential drug release from in vitro studies (A) 90:10 CAPP devices and (B)
90:10 CAPP devices with PSA layer between the blank layers.
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The use of the PSA between the blank CAPP layers further increased the erosion
time of devices to 300 hours. Release of metronidazole occurred within the first 40 hours,
as in the case of devices without PSA layer, but the presence of PSA layers before the other
drug layers slowed erosion and extended the release periods of other three drugs. Release
of ketoprofen occurred through 125-135 hours, which was close to half of the total erosion
time of the device. Release of the third drug, doxycycline, started at around 115 hours and
lasted until 235 hours, and this was followed by simvastatin from 220 hours through
complete erosion of the devices at around 300 hours. The times at which the peaks were
observed in vitro for all four drugs in the two different device types are summarized in
Table 5.2.
Table 5.2: Time of metronidazole, ketoprofen, doxycycline, and simvastatin peaks for the
two types of devices fabricated and tested.
Device
type
Two
blanks
PSA with
two blanks

Metronidazole
(hour)

Ketoprofen
(hour)

Doxycycline
(hour)

Simvastatin
(hour)

Total
erosion
time
(hours)

19

61

99

173

235

19

90

181

293

300

5.3.3 In vivo thickness and mass loss profiles
Cross-sections of the retrieved devices from all three groups (high dose, low dose,
and slow-eroding low dose) showed gradual reduction in thickness of the CAPP layers
(Figure 5.3). The high and low dose groups with two blank layers followed a similar loss
in thickness, with almost all the CAPP layers eroded by day 10. The slower-eroding, low
dose group with PSA layers eroded at a slower rate and had CAPP layers present in them
even at day 18. Figure 5.6 A shows the thickness loss profiles for the three types of devices
over the course of study. The high and low dose devices with two blank layers followed a
biphasic pattern with thickness loss occurring at a faster rate until day three or four
(approximately loss of first four layers, which includes the metronidazole and ketoprofen
layers) followed by a slower rate of thickness loss until complete erosion by day 10. There
was no statistically significant difference between the thickness loss profiles of the high
and low dose groups. The slow-eroding, low dose group followed a similar biphasic
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thickness loss pattern as observed in the case of faster-eroding devices, but at a slower rate
with only 80% of thickness loss occurring by day 18. The slope of the thickness loss curve
of the slow-eroding devices with PSA layers was significantly different from those for
devices with just two blank layers (p=0.04).
The mass of devices measured after retrieval was used to construct the mass loss
profiles shown in Figure 5.6 B. The high and low dose groups with two blank layers
followed similar mass loss profiles, with no significant difference between the slopes of
the curves. The slow-eroding low dose devices with PSA layers followed a mass loss
profile but with a slower rate that was significantly different from that for devices with two
blank layers (p=0.002).
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Figure 5.6: In vivo (A) thickness and (B) mass loss of high dose 90:10 CAPP devices, low
dose 90:10 CAPP devices, and low dose slow eroding 90:10 CAPP devices with PSA layer
between the blank layers.
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5.3.4 In vivo drug release profiles
HPLC measurement of the amount of drug present in the retrieved device was used
to construct in vivo drug releases profile based on the percentage of different drugs
remaining in the retrieved devices. For high dose devices (Figure 5.7 A), metronidazole
was essentially gone at 12 hours, but 100% of the other three drugs was present. After one
day of implantation, the retrieved devices showed about 50% of ketoprofen present and
nearly 100% of doxycycline and simvastatin. There was no significant amount of
ketoprofen observed after the second time point. The presence of doxycycline in the
retrieved implants was observed until day 4. Approximately 100% of the simvastatin was
found in the retrieved devices until the final stages of the study (day 9-10). In the case of
low dose devices, a similar type of release pattern was observed (Figure 5.7 B), with
metronidazole completely released by first time point (24 hours) and nearly 100% of the
other three drugs still present in the implant. Implants retrieved at the second time point
(day 2) showed retention of 100% doxycycline and simvastatin, with ketoprofen
completely released with the exception of some trace amounts. There were traces of
doxycycline observed in the remaining time points, with simvastatin measured in the
retrieved devices until the last time point.
Devices with intermediate PSA layers followed a sequential release pattern of four
drugs but at a slower rate (Figure 5.7 C). Similar to the high and low dose devices,
metronidazole was completely released within 24 hours. Ketoprofen was observed in the
devices until day 3 and traces observed in devices retrieved on day 5. Through day 12,
nearly 100% of doxycycline was found in the retrieved devices, and at day 18 (last time
point) approximately 50% of the doxycycline was observed. With the devices not being
completely eroded by day 18, almost 100% of simvastatin was observed in all the retrieved
devices. Release of the last drug (simvastatin) was observed to be more delayed in all the
three types of devices when compared with the other three drugs released. Table 5.3 gives
an overview of the time points through which the specific drugs were observed in vivo for
the different types of devices.
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Figure 5.7: Sequential drug release from in vivo studies: (A) high dose devices, (B) low
dose devices, and (C) low dose devices with PSA layers.

Table 5.3: Comparison of in vitro and in vivo release of metronidazole, ketoprofen,
doxycycline, and simvastatin, indicating the time points through which the release of
particular type of drug occurred for the specific types of devices. Note: times given in
hours.

Drug type

Faster eroding devices
in vivo
in vivo
In vitro
(high dose) (low dose)

Slower eroding devices
In vitro

in vivo

Metronidazole

30

≤12

≤24

30

≤24

Ketoprofen

90

72-96

72-96

135

120

144-180

144-180

Doxycycline

150

240

432

(with traces observed in later
time points)

(with traces observed in
later time points)

>240

>240

300

>430

Simvastatin

235
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5.3.5 Comparison of in vitro and in vivo drug release profiles
In vitro and in vivo release profiles for devices with two blank CAPP layers are
compared in Figure 5.8A. For these faster-eroding devices, metronidazole release (from
the first layer exposed) was completed within the first 12-24 hours in vitro and by 30 hours
in vivo. Ketoprofen release in vivo occurred slightly faster than in vitro; in both the cases,
ketoprofen release was complete within 90-100 hours. For the third drug, doxycycline, in
vivo release occurred at a slightly slower rate when compared to that of the in vitro release.
Doxycycline was completely released by 150 hours in vitro, compared to release of 8090% at this time in vivo. Simvastatin release (from the last layer) in vivo was much slower
than under in vitro conditions. By 240 hours, simvastatin was completely released in vitro,
but simvastatin layers remained in the devices retrieved at 10 days of implantation.
Figure 5.8B compares in vitro and in vivo cumulative release profiles for devices
with PSA layers that slow erosion. Similar to the faster-eroding devices, metronidazole
release also occurred within 24hours for the slower-eroding devices under both conditions.
Release of ketoprofen again occurred faster in vitro when compared to in vivo. It took
approximately 150 hours for complete release of ketoprofen from slower-eroding devices
in vitro, whereas 90% of the drug was released by 72 hours from slower-eroding devices
in vivo. Similar to the faster-eroding devices, doxycycline (third drug) release in vivo was
slower than its in vitro release. Only 53% of doxycycline was released in vivo by 288 hours
compared to complete release in vitro by 240 hours. Simvastatin release from slow-eroding
devices in vitro was completed by 300 hours, but all devices retrieved at day 18 (last time
point) had the complete simvastatin layer still present, indicating that simvastatin release
had not yet started before 432 hours. Table 5.3 summarizes the temporal differences
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between the faster- and slower-eroding devices in vitro and in vivo based on the time points
through which release of a particular type of drug occurred.

Figure 5.8: Comparison of in vitro and in vivo cumulative drug release of metronidazole
(M), ketoprofen (K), doxycycline (D) and simvastatin (S) from (A) faster and (B) slower
eroding multilayered CAPP devices.
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Figure 5.9 directly compares in vitro mass loss and in vivo thickness loss for the
fast- and slow-eroding devices. In vivo thickness loss was used instead of mass loss because
blood and tissue adherent on retrieved devices made in vivo mass measurements inaccurate.
These plots show the increased erosion rate during the initial stages and relatively slower
erosion rate that was observed during the final stages for both types of devices in vivo.

Figure 5.9: Comparison of in vitro mass loss and in vivo thickness loss of (A) faster and
(B) slower eroding multilayered CAPP devices.
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5.4 Discussion
Multilayered devices based on the CAPP association polymer system have
demonstrated the ability to deliver different types of drugs in a required sequence in vitro
(Sharath C. Sundararaj 2013). Previous research involving this system was conducted using
a CAP:P ratio of 70:30. In this particular study, the system was modified to have a ratio of
90:10 to achieve longer erosion times. The main aim of this research was to investigate
the performance of this CAPP system under in vivo conditions and relate the findings to
what is seen with standard in vitro release experiments. Pilot in vivo studies (data not
shown) showed that devices with the CAP:P ratio of 90:10 had longer erosion time when
compared to devices fabricated using 70:30. These in vivo data were comparable to the
present in vitro data, which showed that the 90:10 CAPP devices (complete erosion time
of 240 hours) had a two-fold increase in erosion time compared with similar devices made
with 70:30 CAPP (complete erosion time of 120 hours) (Sharath C. Sundararaj 2013).
Based on these in vitro and pilot in vivo results, multilayered devices were fabricated with
90:10 CAPP films for a larger scale study to compare in vitro and in vivo material
responses. To achieve an even longer erosion time, PSA layers, which erode more slowly
than does CAPP, was incorporated between the blank layers.
In addition to the primary component of CAPP, the surface-eroding polyanhydride
PSA (Kipper, Shen et al. 2002) was a part of the delivery system. PSA was used as a barrier
in all devices and as a blank layer in the slower-eroding devices. The rate of erosion of
PSA is slower than that of CAPP, making it an appropriate material of choice for a barrier
layer to achieve unidirectional erosion. Furthermore, the thin (approximately 300 µm)
intermediate layers between the blank CAPP layers further decreased the erosion rate. The
presence of three layers of PSA decreased the overall rate of mass loss, thereby increasing
the total erosion time of the device with only a slight increase in total thickness of the
device (< 1 mm) when compared to the devices with just two blank CAPP layers. The
adjustable nature of the delivery system with respect to the erosion time creates the
possibility of designing devices based on specific disease conditions.
In vitro mass loss and drug release
In vitro, devices with two blank layers showed sequential release of the four drugs
metronidazole, ketoprofen, doxycycline, and simvastatin. As intended, slower-eroding
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devices with PSA layers also showed sequential release of the four drugs, with better
distinction between the drug release peaks compared to devices without PSA layers.
Attachment of the final simvastatin-loaded CAPP layer to the PSA barrier might have
affected the erosion rate of this particular layer, which resulted in the less uniform release
of simvastatin compared to the other drugs. This can be resolved in future device
fabrication by incorporating a thin blank CAPP layer between the simvastatin layer and
PSA barrier; in this way, the drug layer and PSA barrier are separated, which should avoid
non-uniform erosion and drug release. It was also observed that the simvastatin and
doxycycline release peaks were broader and took more time to release. This could be
because of the cylindrical, well-shaped design of the PSA barrier leading to retention of
PBS within the barrier shell as the initial CAPP layers eroded, resulting in reduced
circulation of fluid near the final drug layers leading to slower erosion of polymer and
release of drugs.
In vivo thickness loss, mass loss, and drug release
The bottom CAPP layers were seen at day 18 in the case of devices with PSA layers
compared to near complete erosion in devices with just CAPP layers by day 10. This
observation shows that the PSA-containing devices retained their slower-eroding
properties in vivo, as it was previously demonstrated in vitro. Quantitatively, the loss of
thickness followed a pattern comparable to that seen qualititively of the findings observed
in the cross-sectional images. The biphasic thickness loss patterns observed for both the
high and low dose devices were not significantly different, indicating that the amount of
drug loaded in the device did not have any effect on the erosion rate of the device. Thus,
dosing can be adjusted for different future applications. Devices with PSA layers also
followed a similar biphasic thickness loss pattern but at a slower erosion rate,
demonstrating the ability of the PSA layers to slow down the erosion rate of the device
without drastically altering the erosion pattern. Even though the presence of blood and
tissue attached to the remaining CAPP layers and the PSA barrier of retrieved devices made
it difficult to accurately measure mass, the pattern of mass loss observed was comparable
to that of the thickness loss. The biphasic thickness and mass loss patterns could be mostly
due to reduced circulation of fluid because of cylindrical well-based design of the PSA
barrier layer as described in the previous in vitro mass loss and drug release section. Along
75

with the reduced circulation of fluid after the erosion of the initial CAPP layers, the
ingrowth of fibrous tissues in to the well-shaped PSA shell could have further slowed
erosion of CAPP layers in the deeper end of the devices in vivo.
Analysis of the drugs present in the retrieved devices indicated that the drugs were
released in a step-by-step manner in vivo. For example, when the first drug, metronidazole,
was completely released, the other three drugs were still present in the device. Importantly,
the other drugs were not released by diffusion. This type of behavior was observed for the
rest of the four drugs. For all three types of devices, i.e., high dose, low dose, and sloweroding, drug release occurred in the intended sequential manner in vivo. This indicates
that the dose of the drug or the rate of device erosion did not have a substantive effect on
the sequential drug release pattern. Even in vivo, the CAPP layer loaded with simvastatin
attached to the PSA barrier resulted in non-uniform erosion and drug release as observed
in vitro. The extended release of doxycycline and simvastatin relative to the release of first
two drugs, metronidazole and ketoprofen, was comparable to the in vitro release of these
drug in the particular sequence. This also corresponds with the biphasic mass loss and
thickness loss that was observed in vivo.

Comparison of in vitro and in vivo performance
On the whole, devices initially eroded and released drugs more quickly, but during
the later stages, the device design and physiological conditions played major roles in
reducing the rates of polymer erosion and drug release when compared to their in vitro
behaviors. The faster-eroding devices are predicted to last 270-300 hours and the slower
eroding device for 500-600 hours in vivo. Formation of fibrous tissue, observed in the
devices retrieved after one week of implantation, combined with the previously described
retention of fluid within the cylindrical, cup-shaped PSA barrier appeared to have slowed
the clearance of erosion byproducts and the consequent erosion-dependent release of drugs.
These effects were more distinct in the case of slower-eroding devices.
Along with differences in overall erosion rate in vitro and in vivo, the release rate
of specific drugs was affected by their position in the multilayered device. The first two
drugs were released faster and the last two drugs were released more slowly in vivo, when
compared to their corresponding in vitro release profiles. This comparative information
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could be valuable for precisely designing devices capable of releasing multiple drugs in a
predetermined sequential order. For example, the particular drugs selected make the system
relevant for potential treatment of periodontitis (Sharath C. Sundararaj 2013). Knowing the
effect of implantation on the erosion and release profiles enables “tuning” the system to
deliver the active agents at a particular time. The in vivo results clearly suggest that the last
drug released from the device would be delayed when compared to the corresponding in
vitro release from the same device. Based on this, the PSA layer before the simvastatin
layer can be removed to counter the delay that occurs in vivo or the blank CAPP layers can
be replaced by thicker PSA layers to further delay the release if required.
Comparisons of in vivo and in vitro drug release have generally been conducted for
delivery systems containing a single drug, with the in vivo drug release calculated by the
measuring the amount of drug in the plasma or by measuring the amount of drug remaining
in the device/delivery system (Schmidt, Wenz et al. 1995) (Avgoustakis, Beletsi et al. 2002,
Mittal, Sahana et al. 2007, Zolnik and Burgess 2008). Based on the type of polymer used,
type of delivery system, and the physiological effects on the device, release profiles are
similar both in vitro and in vivo in some cases (Schmidt, Wenz et al. 1995). In others, in
vitro release was different from what was measured in vivo (Zolnik and Burgess 2008).
The present study involved a in vivo/in vitro comparison of drug release for a more complex
delivery system involving sequential release of multiple (four) drugs. The comparison
indicates a difference between the in vitro and in vivo drug release profiles. Such
information can be useful for designing complex multiple drug delivery systems and
understanding how they are affected by physiological conditions.

5.5 Conclusions
Multilayered, bioerodible CAPP devices were successful in delivering four drugs
in a sequential manner both in vitro and in vivo. Polymer erosion rate can be adjusted to
shift release peaks, and drug dose can be changed while maintaining the temporal nature
of the profile. Although the overall time course was longer in vivo, erosion and release
were initially faster but then slowed in comparison to standard in vitro conditions. This
type of comparative information will be useful for modifying the delivery system to obtain
programmed sequential release profiles.
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Chapter 6 Conclusion

A CAPP association polymer based device has been developed, capable of
releasing multiple drugs by in a predetermined temporal sequence. The initial studies
showed that the CAPP association polymer fabricated in the form of films can be used to
load and release different types of small molecule drugs and a model protein primarily by
surface erosion. Bioactivity analysis of the released drugs showed the complete retention
of bioactivity in small molecule drugs. The device fabricated in the form of multilayered
CAPP films was able to release the same drug in an intermittent fashion and two different
types of drugs in a sequential order. Even though the CAPP multilayer device was designed
for releasing different types of drugs sequentially in any required order for treatment of
complex disease conditions and tissue engineering purposes, this device was specifically
modified for sequential release of four drugs for stepwise treatment of periodontitis. The
device was capable of releasing antibiotic, anti-inflammatory, anti-resorptive and
osteogenic agents in a temporal sequence aimed at the treatment of infection, inflammation,
tissue loss and alveolar bone regeneration stages of periodontal disease. Different erosion
times of the devices were obtained by changing the CAP:Pluronic ratio from 70:30 to 90:10
and by inclusion of a slower eroding PSA layer in between the CAPP layers. This would
make it possible to change the erosion time of the device, thus altering the drug release
rates based on the requirement of the condition. The sequential release of these four drugs
has also been successfully demonstrated in vivo. Devices loaded with both high and low
doses of drugs followed sequential release pattern in a supracalvarial implantation site,
indicating the possibility of achieving different drug doses depending on the severity of the
condition. Comparison of the in vitro and in vivo drug release profiles provided insights on
the possible changes in the device that might be required for its use in the treatment in
animal model. Future work would involve the modification of this device based on the in
vivo data obtained for treatment in a periodontal animal model and exploring other possible
tissue engineering and treatment application which might need this type of sequential
multiple drug delivery system.
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